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Background: Antibiotic prescribing rates in care homes are higher than in the general population.
Antibiotics disrupt the normal gut flora, sometimes causing antibiotic-associated diarrhoea (AAD).
Clostridium difficile (Hall and O’Toole 1935) Prévot 1938 is the most commonly identified cause of AAD.
Little is known either about the frequency or type of antibiotics prescribed in care homes or about the
incidence and aetiology of AAD in this setting.
Objectives: The Probiotics for Antibiotic-Associated Diarrhoea (PAAD) study was designed as a
two-stage study. PAAD stage 1 aimed to (1) prospectively describe antibiotic prescribing in care homes;
(2) determine the incidence of C. difficile carriage and AAD (including C. difficile-associated diarrhoea);
and (3) to consider implementation challenges and establish the basis for a sample size estimation for a
randomised controlled trial (RCT) of probiotic administration with antibiotics to prevent AAD in care
homes. If justified by PAAD stage 1, the RCT would be implemented in PAAD stage 2. However, as
a result of new evidence regarding the clinical effectiveness of probiotics on the incidence of AAD, a
decision was taken not to proceed with PAAD stage 2.
Design: PAAD stage 1 was a prospective observational cohort study in care homes in South Wales with up
to 12 months’ follow-up for each resident.
Setting: Recruited care homes had management and owner’s agreement to participate and three or more
staff willing to take responsibility for implementing the study.
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Participants: Eleven care homes were recruited, but one withdrew before any residents were recruited.
A total of 279 care home residents were recruited to the observational study and 19 withdrew, 16 (84%)
because of moving to a non-participating care home.
Main outcome measures: The primary outcomes were the rate of antibiotic prescribing, incidence of
AAD, defined as three or more loose stools (type 5–7 on the Bristol Stool Chart) in a 24-hour period, and
C. difficile carriage confirmed on stool culture.
Results: Stool samples were obtained at study entry from 81% of participating residents. Over half of the
samples contained antibiotic-resistant isolates, with Enterobacteriaceae resistant to ciprofloxacin in 47%.
Residents were prescribed an average of 2.16 antibiotic prescriptions per year [95% confidence interval
(CI) 1.90 to 2.46]. Antibiotics were less likely to be prescribed to residents from dual-registered homes.
The incidence of AAD was 0.57 (95% CI 0.41 to 0.81) episodes per year among those residents who were
prescribed antibiotics. AAD was more likely in residents who were prescribed co-amoxiclav than other
antibiotics and in those residents who routinely used incontinence pads. AAD was less common in
residents from residential homes.
Conclusions: Care home residents, particularly in nursing homes, are frequently prescribed antibiotics
and often experience AAD. Antibiotic resistance, including ciprofloxacin resistance, is common in
Enterobacteriaceae isolated from the stool of care home residents. Co-amoxiclav is associated with greater
risk of AAD than other commonly prescribed antibiotics.
Trial registration: Current Controlled Trials ISRCTN 7954844.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 18, No. 63.
See the NIHR Journals Library website for further project information.
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Glossary
Antibiotic-associated diarrhoea Three or more loose stools (defined as type 5–7 on the Bristol Stool
Chart) in a 24-hour period following the prescription of an antibiotic, and for an additional 8 weeks.
Clostridium difficile-associated diarrhoea An episode of antibiotic-associated diarrhoea attributable to
C. difficile as a result of a culture-positive sample.
Unique episodes of antibiotic-associated diarrhoea Episodes of antibiotic-associated diarrhoea
separated by at least 3 days of no recorded diarrhoea.
VSL#3 A probiotic food supplement.
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Plain English summary
Care home residents are mostly frail and at high risk of infections. Their care should be based onhigh-quality evidence, but very little research is carried out in this care sector. We aimed to find out
how often antibiotics are prescribed for care home residents and how often residents develop
antibiotic-associated diarrhoea (AAD).
We also aimed to explore, through interviews and focus groups with care home staff, residents, relatives
and general practitioners, stakeholders’ views of ethical and practical issues in conducting research in
care homes.
We found that the number of antibiotics prescribed in care homes is high. Just over two antibiotic
prescriptions would be expected on average if a care home resident were observed for 1 year. The most
common infections needing antibiotics were urinary tract infections followed by upper respiratory tract
infections. A wide range of antibiotics was used, with amoxicillin the most commonly prescribed. Use of
the antibiotic co-amoxiclav resulted in double the risk of developing AAD compared with treatment with
other antibiotics.
About half of all residents treated with antibiotics developed diarrhoea. About 15% of residents who
developed diarrhoea while on antibiotics and from whom a stool sample was taken were found to be
infected with the potentially serious bacteria Clostridium difficile.
We found that stakeholders were supportive of research being conducted in care home settings, and
advanced consent procedures would be broadly acceptable to key stakeholders in any future trial
of probiotics.
A number of strategies have been identified that those planning analogous research in care homes may
wish to consider.
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Scientific summary
Background
With an ageing population, and demand for long-term care in the UK expected to rise by up to 150%
over the next 50 years, the need for evidence to support and inform best practice in care homes has never
been more of a priority.
Current evidence suggests that between 5% and 10% of residents in care homes will be prescribed
antibiotics for a presumed infection at any one time. Antibiotic use has consequences for residents’ quality
of life (QoL), cost of care and risk of subsequent infections being antibiotic resistant. By disrupting the
normal flora of the gut, antibiotic treatment sometimes causes diarrhoea. Despite older patients with
frequent hospitalisations and high comorbidity being at greatest risk of developing antibiotic-associated
diarrhoea (AAD), little is known about the frequency and type of antibiotics prescribed in care homes in
the UK, or about the incidence and aetiology of AAD. Clostridium difficile (Hall and O’Toole 1935) Prévot
1938-associated diarrhoea (CDAD) is the most commonly identified cause of AAD.
Probiotics given in conjunction with antibiotic treatment have been suggested as a cheap and safe
intervention for the prevention of AAD and CDAD, as they reinforce the human intestinal barrier and help
maintain the commensal gut flora.
Objectives
This two-stage study aimed first to establish the frequency and importance of AAD in care homes before
evaluating an intervention targeted at preventing the condition.
Our objectives for stage 1 were to:
l conduct a prospective systematic ascertainment of all antibiotics used, AAD and outcome over a
12-month period
l determine asymptomatic carriage of C. difficile
l estimate the risk of AAD from particular antibiotics
l pilot and develop trial procedures, including modelling of consent procedures
l test the acceptability and feasibility of administering VSL#3 (a probiotic)
l allow an appraisal of the estimated sample size for a randomised controlled trial (RCT) of probiotics
given with antibiotics to prevent AAD.
Our objectives for Probiotics for Antibiotic-Associated Diarrhoea (PAAD) stage 2 were:
l Primary
¢ to assess the effectiveness of probiotics taken in conjunction with antibiotic treatment in reducing
the incidence of AAD
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l Secondary
¢ to assess the effectiveness of probiotics taken in conjunction with antibiotic treatment in reducing
the incidence of CDAD
¢ to evaluate the impact of probiotics taken in conjunction with antibiotic treatment on functional
status and quality QoL
¢ to evaluate the cost-effectiveness of probiotics taken in conjunction with antibiotic treatment in
reducing the incidence of AAD.
However, a major study [probiotic lactobacilli and bifidobacteria in AAD and C. difficile diarrhoea in the
elderly (PLACIDE)] addressing a similar question as PAAD stage 2, but in hospitals, reported shortly prior to
commencement of care home resident recruitment. The findings of PLACIDE were considered to be
applicable to care home residents. A decision was therefore taken not to proceed with PAAD stage 2.
Methods
Probiotics for Antibiotic-Associated Diarrhoea stage 1
A prospective observational cohort study was conducted in care home residents in South Wales. Residents
were eligible for the study if they had been admitted to the care home for at least 24 hours, had a
planned admission for at least 1 month and written consent could be provided; or, if residents lacked
capacity, advice was taken from a consultee about whether or not the resident would wish to participate
in the study.
At study entry the medical history for each recruited resident was recorded and a stool sample was
collected. All antibiotics prescribed for the resident after recruitment were recorded. Following an antibiotic
prescription, staff recorded the bowel motions of residents (time and consistency of stool) for the period
that antibiotics were prescribed, and for an additional 8 weeks. We defined AAD as three or more loose
stools in a 24-hour period during this follow-up period. When loose stools occurred, stool samples were
collected and sent to a central laboratory to test for C. difficile.
To fit a 95% confidence interval to an AAD rate of 25%± 10%, we estimated that a minimum of
270 care home residents from nine care homes would be required.
An interim analysis was conducted to provide initial evidence of the burden of antibiotic prescribing and
AAD in care homes and to provide estimates for the calculation of a sample size for PAAD stage 2 RCT.
Specific criteria for the progression from PAAD stage 1 to PAAD stage 2 were defined and agreed a priori.
Qualitative study exploring practical and ethical issues of conducting
research in care home settings
To understand the views of a range of stakeholders, a qualitative study was conducted. The qualitative
study participants consisted of residents, relatives, care home staff and general practitioners (GPs) who had
a responsibility for the general medical care of residents and who may be asked to assess eligibility for
research studies. We recruited participants through care homes that participated in the aforementioned
observational study. Data collection was undertaken through a combination of face-to-face interviews with
residents, relatives and GPs and with focus groups among care home staff.
Data were collected on the various merits and problems associated with a number of models of consent
that could be used for a trial that lasts a reasonably long period, and also covered how discussions
regarding consent should take place. Participants were asked what time frame they felt advanced consent
should cover and for their opinion on what should happen should the resident lose (and potentially regain)
capacity during a research trial.
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Probiotics for Antibiotic-Associated Diarrhoea stage 2
A multicentre double-blind placebo-controlled individually randomised trial was proposed.
Participants were eligible for inclusion if they had been prescribed an oral antibiotic for an acute infection and
they had been admitted to the care home for at least 24 hours, had a planned admission for at least 1 month,
written consent could be provided (by the participant or a personal legal representative) and, if they regularly
consumed probiotics, they were willing to discontinue probiotic use for the duration of the trial.
Participants were deemed ineligible for the trial if they had previously been randomised into the trial,
they had a usual stool pattern of ‘diarrhoea’ (as per our previous definition), they both lacked capacity and
were a regular user of probiotics, or they had a medical condition listed as an exclusion criterion.
Participants would be randomised to receive a prescription of VSL#3 (a probiotic containing eight different
strains of potentially beneficial bacteria), to be taken as one sachet twice a day for 21 days, or a matched
placebo, to be started within 72 hours of a new, acute prescription of an antibiotic.
The primary outcome was the occurrence of at least one episode of AAD during the 8 weeks following
randomisation (defined as per PAAD stage 1).
Secondary outcomes included:
l occurrence of CDAD
l duration, frequency and recurrence of AAD
l health-related QoL was also to be measured using the European Quality of Life-5 Dimensions as a
self-reported or proxy measure
l health-care resource use.
The proposed sample size was 400 residents (200 per arm). This would provide 80% power at the 5%
significance level to detect a 50% relative reduction in the incidence of AAD in those given probiotic
intervention alongside antibiotic treatment. This was based on an estimated AAD incidence of 25% in the
placebo arm and is adjusted to allow for a 20% drop-out rate.
Results
Probiotics for Antibiotic-Associated Diarrhoea stage 1
A total of 279 residents were recruited from 10 care homes: four nursing, four residential and
two dual-registered homes. Residents had a median age of 86 years and the majority were female.
Approximately 29% had capacity to consent for themselves.
Stool samples were obtained at study entry from 81% of residents. An average of 2.2 isolates was
cultured per sample, with Escherichia coli (Migula 1895) Castellani and Chalmers 1919, Enterococcus spp.
(ex Thiercelin and Jouhaud 1903) Schleifer and Kilpper-Bälz 1984 and Pseudomonas Migula 1894 the
three most commonly cultured isolates. Over half of the samples contained antibiotic-resistant isolates.
Enterobacteriaceae species resistant to ciprofloxacin were found in 47% of samples. There was wide
variation in the proportion of participants providing stool samples containing antibiotic-resistant isolates
between different types of care homes. The odds of residents carrying antibiotic-resistant isolates in their
stools at study entry increased with age and previous antibiotic use and were significantly lower for
participants in residential homes than for those in nursing homes. C. difficile was cultured in 7% of
samples, with the prevalence varying from 0% in some care homes to 19% in others.
The incidence of antibiotic prescribing was 2.16 prescriptions per resident-year. Antibiotics were prescribed
for a variety of indications. Urinary tract infection (UTI) was the most common indication, followed by
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upper respiratory tract infection (URTI). The most commonly prescribed antibiotics were amoxicillin and
trimethoprim. There was no obvious marked seasonal variation. The odds of being prescribed an antibiotic
was higher for residents who had been prescribed antibiotics in the 4 weeks prior to study entry and lower
for residents in dual-registered homes than in nursing homes.
The incidence of AAD was 0.57 per year for those residents who were prescribed antibiotics. The odds of
developing AAD were higher for those residents prescribed co-amoxiclav and lower for residents in
residential homes than for those in nursing homes. Time from antibiotic prescription to first AAD episode
was shorter in residents prescribed co-amoxiclav and who routinely wore incontinence pads. Time to first
AAD episode was longer in residents from residential homes than those in nursing homes.
For only 55 of the 447 episodes of AAD were corresponding microbiological data available from stool
samples. C. difficile was cultured in eight of these samples, all of which came from residents in the same
care home. However, no ribotype was found in more than one resident, indicating that the C. difficile
cultured was not the result of an outbreak.
Qualitative study exploring practical and ethical issues of conducting
research in care home settings
In total, interviews were conducted with 14 residents, 14 relatives and 10 GPs. Two parallel focus groups
were conducted with 19 care home staff members.
While the majority of residents were happy to be consented just once, relatives, staff and GPs felt that a
verbal rechecking of consent at regular intervals should be performed.
Staff and relatives generally felt that if a resident lost capacity during the trial, his or her relative or legal
representative should be notified of the resident’s participation and current situation.
Probiotics for Antibiotic-Associated Diarrhoea stage 2
At the interim analysis point in PAAD stage 1, all progression (stop/go) criteria for PAAD stage 2 were
sufficiently met, so progression to a RCT was considered justified. The process required to set up the RCT
was lengthy and resource intensive, largely because the trial involved a clinical trial of an investigational
medicinal product (IMP). However, as we were about to open PAAD stage 2 to recruitment of care home
residents, new evidence emerged from the PLACIDE trial regarding the clinical effectiveness of probiotics in
reducing the incidence of AAD and CDAD in older hospital inpatients. The PLACIDE study recommended
that no further studies assessing probiotics for AAD should be undertaken until further evidence is
generated regarding which strains maybe effective in reducing AAD (in vitro evidence). As a result,
discussion took place with members of the Trial Management Group, Trial Steering Committee and the
Health Technology Assessment funding programme, and the decision was made not to progress to
the recruitment phase of PAAD stage 2.
Research prioritisation workshop findings
Following the decision not to progress with PAAD stage 2, a workshop was arranged with members of
staff from care homes that participated in the study (both PAAD stage 1 and during the set-up of PAAD
stage 2) to elicit and rank research priorities for the care home sector.
A total of 23 topics were identified at the workshop, which included a spectrum of service delivery themes
and more specific health-related questions. The topics that were identified as the highest research priority
were improving communication between care home staff and hospital staff during admission or discharge
of a resident, how care home staff can best be kept up to date with staff development and evidence
updates, and the best methods of diagnosing UTIs in this population and collecting reliable urine samples
in female residents.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
Conclusions
Residents of care homes are frequently prescribed antibiotics and frequently experience diarrhoea
following their antibiotic prescription. Not all episodes of diarrhoea following antibiotic use can be ascribed
to antibiotics, and our study does not seek to demonstrate causality, merely association. CDAD was
detected in about 15% of episodes with associated stool samples. Residents in nursing homes were most
likely to be prescribed antibiotics and experience AAD, but the size of the differences may in part be due
to the intensity of monitoring of residents in these types of homes, rather than clinical differences in
the residents. Residents of care homes, in particular nursing homes, have high levels of carriage of
antibiotic-resistant organisms, particularly ciprofloxacin-resistant species. Recent antibiotic use was
associated with an increased likelihood of residents carrying antibiotic-resistant organisms in their stool.
C. difficile was more common in nursing homes, but there was little suggestion of clustering of type
by home.
Residents, relatives, care home staff and GPs are generally supportive of older adults in care homes
participating in research studies. However, respondents were concerned about the best way of facilitating
this, and about the amount of detail that participants can reasonably understand and retain from
consent discussions.
Setting up a RCT in a care home setting was a complex and resource-intensive process, during which
period scientific evidence emerged which impacted on the justification for conducting PAAD stage 2.
Continuing engagement with care homes has resulted in establishing research priorities in the care
home setting.
Implications for health care
Antimicrobial stewardship is an important issue in care homes. Close attention needs to be paid to the
necessity of antibiotic treatment, taking the risk of side effects such as diarrhoea and the development of
antimicrobial resistance into full consideration.
Recommendations for research
There is an urgent need for the provision of evidence to support and inform best practice in care homes.
A greater understanding of the appropriateness (e.g. type, dose and duration) of antibiotic prescribing in
this setting is needed in order to develop antimicrobial stewardship interventions. Conducting and
disseminating research in this setting is challenging, particularly when the research involves IMPs.
These challenges need to be overcome if meaningful evidence-based care is to be implemented.
Research priorities identified by care home staff include the need to improve the communication between
care home and hospital staff, improving the provision of current relevant evidence to care home staff and
methods for diagnosing UTIs in this population.
Those planning analogous research in care homes may wish to consider:
l consulting an ‘expert’ with experience of working in a care home at the design stage of the study
l allowing plenty of time to initially approach care homes, set up the sites, recruit residents and
undertake the study
l ensuring that processes are easy for staff to complete and where possible following their own
processes, so as to not add to staff workload
l embedding additional study staff or employing research nurses in the care homes to collect information
from residents and carry out any sampling.
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Chapter 1 Introduction
Overall introduction to the Probiotics for Antibiotic-Associated
Diarrhoea study
The Probiotics for Antibiotic-Associated Diarrhoea (PAAD) study aimed to develop the platform for,
and possibly implement, a randomised controlled trial (RCT) of probiotics administered with antibiotics
to prevent antibiotic-associated diarrhoea (AAD). To justify a trial, we first needed an estimate of the
magnitude of the AAD problem in care homes. We therefore set out to do a two-stage study. The purpose
of PAAD stage 1 was to determine the prevalence of antibiotic prescribing and indication, the prevalence
of AAD and to provide an indication of the prevalence of antibiotic-resistant organisms in the stool of care
home residents. This would provide useful information in its own right to help guide care in this vulnerable
population, in which infections are frequent and antibiotic prescribing is common and often not evidence
based. It would also provide the basis for determining whether or not a RCT of probiotics to prevent AAD
was justified and, if so, to generate data required for a sample size calculation for such a trial. The trial
component of the study formed PAAD stage 2.
Antibiotic use in care homes
At least 4% of UK and US populations aged 65 years or over live in care homes.1–3 Demand for long-term
care in the UK is estimated to rise by up to 150% over the next 50 years.4
Although data on infection prevalence in care homes are limited, point prevalence studies suggest that
between 5% and 10% of residents in care homes will be prescribed antibiotics for a presumed infection at
any one time.5,6 This antibiotic use has consequences for residents’ quality of life (QoL) from both benefits
and harms associated with antibiotic use, costs of care and increased risk that subsequent infections will
be antibiotic resistant.7–9 However, up to 40% of antibiotics prescribed in care homes might be
inappropriate.8–10 Accurate estimates of prescription rates by antibiotic class and indication are lacking.
Antibiotic-associated diarrhoea
Antibiotic treatment disrupts the normal flora of the gut, sometimes causing diarrhoea.11 The primary
mechanism is thought to be disturbance in the metabolism of carbohydrates, short-chain fatty acids and
bile acids, resulting in impaired resistance to pathogens.12 While any antibiotic can cause AAD,
clindamycin, cephalosporins, aminopenicillins and, more recently, fluoroquinolones have been directly
linked with AAD, particularly in hospitalised patients.13 Older patients with frequent hospitalisations and
high comorbidity are at greatest risk.13 Little is known about the frequency and type of antibiotics
prescribed in care homes, or about the incidence and aetiology of AAD. AAD varies in incidence, is
especially common in winter, and can occur in up to 39% of hospitalised patients receiving antibiotics.14
A challenge to clinicians is to identify cases of AAD due to Clostridium difficile (Hall and O’Toole 1935)
Prévot 1938 infection since this is the most commonly identified and treatable pathogen responsible and is
also implicated in more severe cases of AAD.11 C. difficile is implicated in 20–30% of AAD cases.15
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Clostridium difficile
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacteria that was identified in the late
1970s and has recently been highlighted as a potential deadly threat to hospitalised patients and residents
of care homes.13,16 The spores can survive for lengthy periods in the environment and gut; therefore,
there is a high risk of cross-infection through direct patient-to-patient contact, via health-care staff or via
a contaminated environment. The Health Protection Agency’s (HPA) data from voluntary surveillance of
C. difficile in England, Wales and Northern Ireland in 2006 described an overall increase in incidence,
from 2005 to 2006, of 8% in England and 15% in Wales, with the highest incidence in the elderly.17
Although there were some HPA data for positive stool samples originating in primary care, there are no
data to indicate whether or not these are follow-up samples from hospitalised patients. We were not able
to identify prospective UK data on C. difficile outside hospitals, nor were we able to identify studies that
involved prospective, systematic sampling. The second study of Infectious Intestinal Disease (IID2) included
the incidence of C. difficile among people living in the community but not in care homes.18
Clostridium difficile-associated diarrhoea
Clostridium difficile-associated diarrhoea (CDAD) is the most commonly identified cause of AAD, and is
responsible for most cases of pseudomembranous colitis; it typically occurs in care homes, among other
settings.19 CDAD occurs most often as a consequence of disruption of the indigenous colonic microflora
following broad-spectrum antibiotic treatment. C. difficile accounts for 20–30% of AAD,15 although
some estimates are more conservative.11 Although the majority of individuals recover fully, elderly and
frail individuals in particular may suffer loss of dignity or become seriously ill with dehydration
(as a consequence of the diarrhoea), and some may go on to develop pseudomembranous colitis.
Exposure to antibiotics within the previous 2 months is the most important risk factor for developing
CDAD.20 Cumulative antibiotic exposure appears to be associated with an increased risk of CDAD.21
Other well-recognised risk factors include age [hospital patients aged over 65 years are four times more
likely than general medical patients to develop CDAD (73.6 vs. 16 per 1000 admissions)], hospitalisation,
severity of underlying illness, nasogastric tube and use of proton pump inhibitors or H2-agonists.22–24
Clostridium difficile-associated diarrhoea and
antibiotic-associated diarrhoea infection in care homes
There are few data regarding antibiotic use, AAD and CDAD in UK care homes. Most of the research to
date has been carried out in hospital settings or in the USA. However, residents in care homes in the UK
have many of the risk factors associated with developing AAD and CDAD (e.g. age over 65 years, frailty,
multiple comorbidities and frequent antibiotic treatment).
Antibiotic use in US residential homes is common: estimations of single time point prevalence range from
8% to 17%, and in one study between 50% and 75% of residents received at least one antibiotic
prescription over a 12-month period.20 We conducted a prescribing audit of care homes in one health
authority and found that 134 (7%) of 1901 residents were on an antibiotic in a single day. A study in
care homes in Sweden found that 25% of residents were prescribed an antibiotic during a 3-month
observation period.25 However, considerably fewer antibiotics are prescribed in Sweden than in the UK.26
It is not known how many of these residents developed AAD or how many had C. difficile in these studies.
Providing reasonable estimates of these outcomes for the UK relate to the scientific importance of our
study to the NHS. Diarrhoea within long-term care facilities (LTCFs) can cause fatalities and could
become endemic.
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Laffan et al.27 retrospectively reviewed CDAD incidence and prevalence in a single 200-bed LTCF in Baltimore
in the USA between July 2001 and December 2003. The incidence of CDAD ranged from 0 to 2.62 cases
per 1000 resident-days. They found that CDAD in this LTCF occurred most often in patients who had
recently been admitted to hospital.27 US studies by Kutty et al. and Chang et al. found that over 90% of
post-hospitalisation cases of CDAD occur within 30 days of discharge.28,29
Riggs et al., in the USA, found that over 50% of patients admitted to a LTCF during an outbreak were
asymptomatic carriers of C. difficile (stool culture positive, but no diarrhoea).30
A review of the diagnosis, management and prevention of C. difficile in LTCFs concluded that the
epidemiology, risks and outcomes of C. difficile infection in older residents of LTCFs need to be better
understood.31 Better treatment modalities to reduce the risk of recurrent disease need to be developed
and assessed, and measures such as antimicrobial stewardship should be introduced.
Probiotics to prevent antibiotic-associated diarrhoea
Probiotics are dietary supplements containing a single culture or mixed culture of live microorganisms
such as bacteria or yeast which, when administered in adequate amounts, confer a health benefit on the
host by improving the properties of the indigenous microflora.32 Probiotics have been proposed as a
preventative intervention for AAD, including CDAD, as they reinforce the human intestinal barrier.14,33–35
Probiotics’ likely mechanism of action is through secretion of antimicrobial factors, such as bacteriocins,
and competition for adherence to the binding sites on mucins and epithelial cells, thereby preventing
detrimental colonisation and contributing to barrier function.36 Certain probiotic strains are resistant to
digestion by enteric or pancreatic enzymes, gastric acid and bile, and prevent the adherence, establishment
and/or replication of pathogens in the gastrointestinal tract. Probiotics are generally well tolerated and free
of adverse effects although, theoretically, the introduction of live bacteria may carry the risk of introducing
resistance genes and causing septicaemia.37
A previous Cochrane review of probiotics as a treatment for presumed infectious diarrhoea included
23 studies with a total of 1917 participants and found that probiotics reduced the risk of diarrhoea
at 3 days [relative risk (RR) 0.66, 95% confidence interval (CI) 0.55 to 0.77, random-effects model;
15 studies] and the mean duration of diarrhoea by 30.48 hours (95% CI 18.51 to 42.46 hours,
random-effects model; 12 studies).35 A Cochrane review of probiotics for the prevention and treatment of
AAD38 included 63 studies with a total of 11,811 participants and indicated a statistically significant
association of probiotic administration with reduction in AAD [RR 0.58, 95% CI 0.50 to 0.68; p< 0.001;
I2= 54%; (risk difference –0.07, 95% CI –0.10 to –0.05) (number needed to treat 13, 95% CI 10.3 to
19.1)] in trials reporting on the number of patients with AAD. However, there is significant heterogeneity
in the pooled results and the evidence is insufficient to determine whether this association varies
systematically by population, antibiotic characteristic or probiotic preparation. The review concluded that
probiotics are associated with a reduction in AAD; however, more research is required to determine which
probiotics, patients and antibiotics are associated with the greater efficacy.
A recent Cochrane review of probiotics for the prevention of CDAD in adults and children included
23 studies with a total of 4213 participants and found that probiotics significantly reduce the risk of
CDAD by 64%.39 The incidence of CDAD was 2.0% in the probiotic group, compared with 5.5% in the
placebo, no treatment, control group (RR 0.36, 95% CI 0.26 to 0.51). The review concluded that the
moderate-quality evidence suggested that probiotics are both safe and effective for preventing CDAD.
A systematic review of six studies of paediatric patients found significant benefit to patients from using
probiotics in per-protocol analyses compared with control patients (RR 0.43, 95% CI 0.25 to 0.75).
However, no evidence for a difference was found in intention-to-treat analyses (RR 1.01, 95% CI 0.64 to
1.61).40 Hickson et al.41 randomised patients to receive either antibiotics and placebo (n= 66) or antibiotics
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and probiotics (n= 69) and found that 7 of 57 patients in the probiotic group, compared with 19 patients
from 56 in the control group, developed AAD. However, only 135 of 1760 hospitalised patients taking
antibiotics were randomised in this trial (randomisation rate 7.6%), which may limit the applicability of
the findings.41
Database searches
We searched MEDLINE and EMBASE prior to starting this study, and our findings indicated that the
evidence base for the use of probiotics is incomplete. In the light of our searches we have made
recommendations about what should be done taking into consideration this uncertainty and about future
research.42 More specifically, we were not able to identify evidence for or against using probiotics to
prevent AAD in people admitted to LTCF/care homes or in primary care. It is essential that research is
carried out in the setting in which the evidence will be applied, the findings of hospital-based studies may
not apply to the care home setting, as antibiotics, routes of administration and patient profiles differ
between hospitals and care homes.
Conducting studies in care homes
There are 1203 care homes in Wales, of which 25% provide nursing care (300 homes). There are a total of
2607 care homes and 570 nursing homes in south-west England. Within these homes, there are
approximately 427,000 beds across England and Wales, and it is understood that the number of beds will
need to be increased in line with the projected rise in demand for long-term care.1,2
Conducting studies in care homes, especially nursing homes, poses unique challenges. Care home research
participants are more likely to be older, physically frail and cognitively impaired compared with other
research settings.43 Recruitment, consent, retention and data collection can be time-consuming and
difficult and extra time and help should be provided to ensure that the staff in care homes have the ability
to carry out the research procedures.44 Care home staff are also more likely to move after short periods
of employment.
Rationale for the Probiotics for Antibiotic-Associated
Diarrhoea study
There are (incomplete) surveillance data from the USA and the UK, and UK clinical experience to suggest
that AAD including CDAD is an important problem in care homes in the UK. There are strong grounds for
evaluating probiotics in conjunction with antibiotic treatment to prevent AAD in care homes, but this
strategy has never been properly evaluated in a clinical trial. However, before a trial is justified, the
importance of the problem to the independent care home sector and NHS, a firm basis for sample size
calculation and trial planning, needs to be more clearly established.
The introduction of probiotics in conjunction with antibiotic treatment in care homes could lead to a
significant reduction in AAD, as antibiotic treatment is common in this group; spread is a particular risk, and
patient frailty increases risk of acquisition and of complications. Diarrhoea in this group can lead to serious
illness resulting in hospital admissions, cause illness in fellow care home residents, increase vulnerability
through reduced nutrition and dehydration, result in ongoing incontinence, cause urinary tract infections
(UTIs) and have a profoundly negative impact on dignity. Therefore, we proposed a two-stage study.
The PAAD study stage 1 would establish the descriptive data we needed to confirm both the magnitude of
the problem and that our sample size calculation assumptions were correct. Knowing the amount and
nature of antibiotics prescribed in care homes and describing AAD and CDAD would be useful in its own
right and would help to guide future antibiotic prescribing decisions in this setting. To account for the
known difficulties in conducting research in this setting, we also planned to pilot study procedures, model
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consent procedures, and develop training material to train care home staff in how to conduct the RCT and
determine if cascading of the training to new colleagues would be possible.
If PAAD stage 1 confirmed a trial was justified, PAAD stage 2 would be a RCT to generate robust evidence
that would fill an important gap in the evidence base about the use of probiotics, in conjunction with
antibiotic treatment, in older people in care homes.
Probiotics for Antibiotic-Associated Diarrhoea study objectives
Probiotics for Antibiotic-Associated Diarrhoea stage 1: primary objectives
1. To conduct prospective systematic ascertainment of the incidence of AAD in care homes.
2. To allow an appraisal of the estimated sample size for a RCT in PAAD stage 2.
Probiotics for Antibiotic-Associated Diarrhoea stage 1: secondary objectives
and auxiliary study objectives
1. To conduct prospective systematic ascertainment of antibiotic use in care homes.
2. To estimate the risk of AAD overall and from particular antibiotics in care home settings.
3. To identify barriers and implementation issues in conducting a trial of AAD prevention/amelioration in a
care home setting.
4. To determine the prevalence of asymptomatic C. difficile carriage in residents within selected
care homes.
The probiotic feasibility and acceptability study
1. To test the acceptability and feasibility of administering probiotic in a small number of care
home residents.
2. To pilot and develop trial procedures including modelling consent procedures.
3. To develop a training package for care home personnel to implement the trial.
The qualitative study
1. To conduct focus groups and individual qualitative interviews with care home residents, their family,
care home staff and general practitioners (GPs).
2. To explore the ethical and practical issues of consent and assent, particularly the topic of advanced
consent, for elderly residents who may/may not have capacity to consent.
Probiotics for Antibiotic-Associated Diarrhoea stage 2 objectives
The primary objective was to:
1. assess the effectiveness of probiotics taken in conjunction with antibiotic treatment in reducing the
incidence of AAD.
The secondary objectives were to:
1. assess the effectiveness of probiotics taken in conjunction with antibiotic treatment in reducing the
incidence of CDAD
2. evaluate the impact of probiotics in conjunction with antibiotic treatment on the functional status
and QoL
3. evaluate the cost-effectiveness of probiotics in conjunction with antibiotic treatment in reducing AAD.
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Changes to objectives
The originally planned feasibility study, to test the acceptability and practicability of administering probiotic
in a small number of residents, was not undertaken for two reasons. First, on discussion with the
pharmaceutical company (Actiel), it was confirmed that the VSL#3 powder could be dissolved in as little as
25–50ml of liquid or sprinkled on food; therefore, the initial concern over drinking a large volume of liquid
(100ml) was appeased. Second, it was considered resource and time intensive to conduct alongside the
main observation study.
Summary
In summary, PAAD stage 1 aimed to identify the rates of antibiotic prescribing and AAD in care homes, to
determine the prevalence of C. difficile in baseline stool samples and to provide reliable incidence data and
confirm the basis of our sample size calculation for the RCT in PAAD stage 2.
If PAAD stage 1 indicated that AAD is a rare, unimportant problem, then, based on explicit stopping rules,
we would not progress to PAAD stage 2.
In addition, work was planned in PAAD stage 1 to allow us anticipate and address challenges in the PAAD
stage 2 trial design and implementation. In particular, we were keen to explore the acceptability of
advanced consent procedures in a possible trial of probiotics to prevent AAD.
INTRODUCTION
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Chapter 2 Probiotics for Antibiotic-Associated
Diarrhoea stage 1: a prospective observational study
of antibiotic prescribing and antibiotic-associated
diarrhoea in care home residents
Methods
Study design
The PAAD study stage 1 was a prospective observational cohort study of antibiotic prescribing and
associated AAD in care home residents (Figure 1). The study was conducted between November 2010 and
March 2012 in care homes in South Wales. We aimed to recruit a total of 270 care home residents and
follow up each resident for 12 months. The South East Wales Research Ethics Committee (REC) approved
the study (10/WSE03/31). Agreement to conduct the study at the care homes was either given by the
care home manager, regional manager or care homeowner (if privately owned) or given by the local
authority (LA).
Study objectives
Primary objectives
1. To conduct prospective systematic ascertainment of the incidence of AAD in care homes.
2. To allow an appraisal of the estimated sample size for a RCT in stage 2.
The aim was to use this information to identify the scale of the AAD problem in care homes, provide
reliable incidence data and confirm the basis of our sample size calculation for a RCT of probiotics in PAAD
stage 2.
Secondary objectives
1. To conduct prospective systematic ascertainment of antibiotic use in care homes.
2. To estimate the risk of AAD overall and from particular antibiotics in care home settings.
3. To identify barriers and implementation issues in conducting a trial of AAD prevention/amelioration in a
care home setting.
4. To determine the prevalence of asymptomatic C. difficile carriage in residents within selected
care homes.
The aim was to use this information, in conjunction with AAD incidence, to estimate the risk of AAD
overall, from antibiotics overall, and from particular antibiotics in care home settings. Additionally, the
observational study would serve as an opportunity to ascertain the practicalities of conducting a RCT in a
care home environment.
We planned an interim analysis at 8 months after commencing recruitment of residents, which would
include follow-up data from residents recruited within the first 6 months, to assess the scale of the
AAD problem in care homes. The results of the interim analysis, in relation to the explicit stopping rules
defined by the research team, would determine whether or not progression to the PAAD stage 2 RCT
was warranted.
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Participants and recruitment
Care home recruitment
The research team identified all care homes in South Wales, stratified them based on the type of care they
provided (nursing, residential or dual registered, i.e. providing both nursing and residential care), randomly
ordered them within their stratum and approached the care homes sequentially by telephone to arrange a
meeting with the manager of the care home to discuss the study further.
During this meeting, the aims and objectives of the study were explained in more detail and an informal
questionnaire was used to prompt the team to gather data about the home in order to assess the
feasibility and practicality of carrying out the study at that care home.
Care homes were recruited when the relevant manager and care home owner agreed for PAAD stage 1 to
go ahead at their site and at least three staff at the site were willing to take responsibility for conducting
the study in their care home. Reimbursement was offered for the time staff dedicated to the study or
additional time spent over their contracted hours and additional research nurse or research officer support
was provided by the National Institute for Social Care and Health Research – Clinical Research Centre
(NISCHR CRC) where needed.
Care homes recruited
Consent of care home resident (or
advice from his/her representative)
to participate in the study
Baseline assessment:
CRF (age, medical history,
medications, nutritional status)
baseline stool sample taken
Participant prescribed
antibiotic by GP
Stool chart completed for
duration of antibiotics and
8 weeks after completing
antibiotic course
Participant develops
diarrhoea while taking
antibiotics or within 
8 weeks of completing
antibiotics
Stool sample sent to
central laboratory for
standard stool analysis
including C. difficile
Participant does not
develop diarrhoea
while taking antibiotics
or within 8 weeks of
completing antibiotics
FIGURE 1 Study design. CRF, case report form.
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Once the essential governance documents were completed, signed and returned to the research team, the
care home was provided with all the information, training and equipment necessary to carry out resident
recruitment and study procedures.
Participant recruitment
Residents were eligible for the study if they met all of the PAAD stage 1 inclusion criteria (Table 1).
There were two categories of eligible residents: those who had capacity to consent and those unable to
consent for themselves. Therefore, consent procedures differed depending on whether or not residents
had capacity at the time the resident was approached and recruited into the study.
Senior care home/nursing staff were asked to identify residents who were eligible to join the study. Where
staff members were unsure of the mental capacity status of an eligible resident, mental capacity was
assessed during the consent procedure to determine capacity to consent. Study information was given
using written information available in several forms (either the full information sheet or a more visually
accessible information sheet in large print and a pictorial information sheet) to ensure that residents were
given a full opportunity to consent for themselves. Residents with mental capacity and willing to
participate were asked to provide written consent or verbal consent (for those unable to write). This was
witnessed by two senior staff members. Where residents lacked capacity, senior care home/nursing staff
were asked to identify representatives, herein referred to as ‘consultee’, for each resident (e.g. next of kin,
those who visit most regularly). Consultees were provided with the study information sheet accompanied
with a verbal explanation when they came into the care home or, if this was not possible, by post and
then followed up with a telephone call. The consultees of the residents were explicitly asked, either in
writing or verbally, to consider whether or not they believed the resident would want to join the study.
Consultees who believed their relative would have wanted to participate in the study were asked to sign a
consent form to document their decision.
For residents who did not have an available consultee, the plan was to contact Age UK for advice or
request that the residents’ GP nominate an appropriate person or act on the resident’s behalf. Both of
these options are suggested in the 2005 Mental Capacity Act (MCA).45 However, this situation did not
arise during the course of the study.
During the recruitment process, residents and their consultees were given as much time as needed
to consider the information and the opportunity to question the care home staff, their GP or other
independent parties to decide whether or not they were willing to participate in the study. All consent,
written or verbal, and assessment of mental capacity was undertaken by study-trained senior care home
staff/nursing staff. All residents and consultees were advised that they could withdraw participation in the
study at any time without it affecting their care.
TABLE 1 Participant inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Resident admitted to the care home for > 24 hours There were no exclusion criteria for the PAAD stage 1
observational study
Planned admission to care home of 1 month or more
(excludes short term respite care)
Written confirmed consent/assent provided
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
9
Study procedures
Study training
The research team aimed to deliver bespoke study training to staff at each individual care home because
of the heterogeneity of the recruited care homes, in terms of both size and type of resident care.
Core standardised training modules included the fundamentals of good clinical practice (GCP) as well as
study-specific training on how to approach residents/consultees about the study, assessing capacity, taking
informed consent, interpreting and using the Malnutrition Universal Assessment Tool (MUST), reporting
serious adverse events (SAEs), interpreting the Bristol Stool Chart (BSC), taking and sending stool samples
and data collection.
Initial training was provided before the start of the study, before recruitment, once the study began and
continuously after that point with specific staff groups to refresh their memory. As much flexibility as
possible was given to the time (i.e. evenings, weekends) and number of training sessions in order to
provide training to as many senior staff members and registered nurses as possible without disrupting the
usual routines in the homes. Owing to the need to retain adequate staffing levels at the homes, it was
often not possible for all of the care assistants to attend training; therefore, we requested that the training
be cascaded from those who had attended training to more junior members of staff.
Monthly teleconference calls were set up with key staff in each of the care homes to be used as a forum
to update care home status, share challenges, find solutions and generally maintain engagement and
enthusiasm for the study. Incentives, in terms of both monetary (vouchers) and non-monetary (certificates,
specialised training courses, cake for site of the month, etc.) value were also provided.
Throughout the course of the study the research team organised three workshops with the aim of
promoting engagement with the study and to provide ongoing training. Workshops were held in Cardiff
city centre and were designed to help care home staff discuss procedures to obtain consent or maximise
accurate case report form (CRF) completion.
Data collection
Prior to the recruitment of residents, care home staff were asked to complete a care home information
CRF. The purpose of this CRF was to elicit summary information about the care home characteristics and,
to that end, it incorporated questions asking about the number of beds, number of residents, staffing
levels and whether or not there was an infection control policy in place. A further CRF was completed at
the end of the study to provide a measure of change in number of residents and staffing levels over the
study period.
Data about residents participating in the observational study were collected in two phases (1) ‘baseline’
data were collected as soon as possible following consent and (2) ‘follow-up’ data were collected when a
resident recruited into the study was prescribed antibiotics at any point during the 12 months following
recruitment (Figure 2).
Serious adverse event reporting was undertaken for all recruited residents regardless of whether or not
they were prescribed antibiotics during the 12-month observational period. The CRFs included standard
screening and assessment tools (among other questions devised by the research team) (Table 2).
Table 3 details, for each PAAD study CRF, time point for data collection, a brief description of the type of
data collected and who had overall responsibility for collecting the data. The research team requested that
the original CRF should be sent to the PAAD study trial manager and a copy kept in the site file in each
care home.
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CRF 02: recruitment CRF
CRF 03: resident characteristics CRF
CRF 04: baseline stool sample CRF
To be sent with a baselines tool sample
CRF 05: antibiotic prescription CRF
Completed for all recruited residents who
also consented to the baseline stool sample
Completed
for all
recruited
residents
CRF 06: weekly stool monitoring chart CRF
To be completed weekly for 8 weeks
(detailing the resident’s stools over 8 weeks)
CRF 07: diagnostic stool sample CRF
To be sent with a diagnostic stool sample
During the 8-week follow-up period: sample taken and
CRF completed each time resident experienced three BSC
type 5–7 stools within a 24-hour period
CRF 10: antibiotic notes search CRF
Completed for all recruited residents following
the 12-month observation period
Ad hoc CRFs (completed as required)
CRF 08: withdrawal CRF CRF 09: SAE CRF
If resident prescribed antibiotics
FIGURE 2 Data flow of recruited residents.
TABLE 2 Screening and assessment tools included in CRFs
Tool Description of tool When recorded
MUST MUST is a five-step screening tool used to assess
nutritional risk. The algorithm requires information
about current body mass index, weight loss and
current health status in order to provide the health
professional with a score used to guide nutritional
management of the patient46
When recruited into the study (CRF 03)
Each time the resident was prescribed an
antibiotic (CRF 05)
Clinical Frailty
Scale
The Clinical Frailty Scale is a visual aid used to assess a
person’s perceived frailty. It has been used as a
predictor of death or need for entry into care facility.
The tool uses nine pictures, each with brief
descriptions, on a Likert-type scale in which options
vary between very fit and very severely frail or
terminally ill47
When recruited into the study (CRF 03)
BSC The BSC is a visual aid used by health professionals as
a diagnostic marker of digestive health. The scale
depicts seven pictures of human faeces in various
forms, ranging from faeces described as type 1
(separate hard lumps, like nuts; hard to pass) to type 7
(watery, no solid pieces, i.e. entirely liquid)
On the CRFs that accompanied the baseline
stool sample (CRF 04)
When a stool bowel movement was
recorded following an antibiotic prescription
(CRF 06) and/or diagnostic stool sample(s)
(CRF 07)
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Data collected following antibiotic prescription
For each antibiotic prescribed during the study period, care home staff recorded the medical indication,
name, route, dose, day and duration of prescription on the antibiotic CRF (05). Immediately following an
antibiotic prescription for the duration of and up until 8 weeks after the end of the antibiotic course, the
care home staff collected data on the resident’s daily stools (including the time the stool was passed and
the BSC type of the stool), using the stool monitoring CRF (06), reported on a weekly basis.
If care home staff observed loose stools (BSC score 5–7) in a participating resident during the stool
monitoring follow-up period, a stool sample was taken on the second episode of loose stools to ensure
that samples were collected whenever an episode of AAD might have occurred. This sample was sent to
the laboratory along with a diagnostic stool sample CRF (07) which stated the stool’s consistency and time
of sample collection.
Samples were sent to a central reference laboratory specialist antimicrobial chemotherapy unit for
C. difficile culture and screening for the carriage of antibiotic-resistant organisms. Staff at care homes were
also encouraged to also send a stool sample to their local laboratory as per their routine procedure.
TABLE 3 Data collection table
CRF Data collected Time point Collected by
CRF 01 – care
home information
Type, size, occupancy of home. Staffing
levels and infection control training
Prior to commencing recruitment Care home
staff
CRF 02 – recruitment Eligibility confirmation, age, gender,
capacity status
Immediately post consent Care home
staff
CRF 03 – resident
characteristics
Medical history, recent hospitalisation,
recent antibiotic use
Immediately post consent Care home
staff
CRF 04 – baseline
stool sample
Date and time of stool collection.
Consistency of stool
Within 1 week from consent Care home
staff
CRF 05 – antibiotic
prescription
Name, dose, route, frequency, duration
and indication of antibiotic
Day of commencement of
antibiotic treatment until duration
end date
Care home
staff/NISCHR
CRC research
officers
CRF 06 – weekly stool
monitoring chart
Time and consistency of bowel
movements. Whether or not a stool
sample was taken
Day of commencement of
antibiotic treatment, every day for
duration of antibiotic+ 8 weeks
Care home
staff/NISCHR
CRC research
officers
CRF 07 – diagnostic
stool sample
Date and time of stool collection.
Consistency of stool
When participant develops
diarrhoea within the 8-week
follow-up period
following antibiotics
Care home
staff
CRF 08 – withdrawal Date and reason for withdrawal Following a withdrawal Care home
staff/NISCHR
CRC research
officers
CRF 09 – SAE
reporting
Details of adverse event (outcome,
description, seriousness, expectedness
and causality)
Following any SAE Care home
staff/NISCHR
CRC research
officers
CRF 10 – antibiotic
notes search
Name, dose, route, frequency, duration
and indication of antibiotics prescribed in
the 3 months prior to study entry
At the end of the recruitment
period at the care home
Care home
staff/NISCHR
CRC research
officers
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Medication data
The care home staff or NISCHR CRC research officers were also asked to take a photocopy of the
medication administration record (MAR) from the care plan of each consented resident. To maintain
anonymity, residents’ names were replaced by their participant identifier (PID). The photocopy of the MAR
was requested as soon as possible following consent, each time an antibiotic was prescribed and for
the entire month of March 2012. The intention of the 1-month review was to inform an audit of the
effectiveness of care home reporting of antibiotics. The purpose of the request following consent and
following an antibiotic prescription was to determine whether or not there were any trends between
certain medications and AAD or CDAD.
Serious adverse event reporting, withdrawals and loss to follow-up
When care home staff became aware that a participating resident had experienced a SAE, they were asked
to complete a SAE CRF within 24 hours on becoming aware of the event.
The research team was notified of study withdrawals and deaths via the withdrawal CRF. Participating
residents who were admitted to hospital were not considered lost to follow-up unless they stayed in
hospital for the remainder of their time in the study.
Data management
Participant tracking
Residents were ‘tracked’ throughout their time in the study using the completed CRFs (and the dates on
the CRFs) that were sent from care homes. Data were added on to the PAAD stage 1 database when
these CRFs were received at the South East Wales Trials Unit (SEWTU). The data manager was able to
search for each recruited resident in the database using the resident’s PID to determine which CRFs had
been completed for each individual and, hence, what stage the resident was at in the study.
Clinical data
Receipt of CRFs was logged in the database. CRFs were first visually checked, then processed using
Cardiff TeleForm, an optical mark recognition system, and stored in Statistical Product and Service
Solutions (SPSS) data sets (SPSS version 20; IBM Corporation, Armonk, NY, USA). Missing/invalid data,
identified during any of the above points and using data validation checks in SPSS, were queried at site
using source data from care notes. Data corrections were undertaken prior to scanning in TeleForm, or via
syntax in SPSS.
Stool data
Stool sample results were collated and stored electronically at the Public Health Wales laboratory. Care
home staff were asked to fax or send the research team at SEWTU a copy of the completed diagnostic
stool sample CRF (07) so that the research team could maintain a record of when stools samples had been
sent to the laboratory.
Stool sampling
All care homes were provided with a protocol on the stool sampling procedure in order to promote
standardisation when collecting and sending stool samples. The research team provided all care homes
with disposable bowl inserts for commode pots, sample tubes, adhesive tube labels and spatulas as well as
a fridge for storing samples that could not be immediately sent to the laboratory. Stool samples were
taken either from stool passed into commode inserts or from the resident’s incontinence pad and placed
into a sample tube. The research team requested that the sample [with the diagnostic stool sample
CRF (07)] should be labelled with the resident’s PID and initials and sent to the central reference laboratory
using Post OfficeTM-approved SafeboxesTM.
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Stool sample analysis
The stool samples were cultured, including for C. difficile, and then stored at −70 °C. Cultured C. difficile
isolates were then ribotyped, toxin tested and subjected to antimicrobial sensitivity testing as well as
screened for carriage of antibiotic-resistant bacteria. As the results of the loose stool study samples were
used for research purposes only and were not fully analysed in real time, they were not sent back to the
care homes or GPs.
Statistical methods
Care home sampling frame
Care homes in South-East Wales were split into three strata, based on the type of care home: nursing,
residential or dual registered. The team intended to purposively recruit three care homes from each
stratum, making a total sample of nine care homes. The aim of this method of sampling was to gain an
insight into the amount of variability between and within different types of care homes (in terms of both
the homes themselves and their residents).
Resident sample size justification
We predicted that nine care homes would generate a sample of approximately 270 residents. Previous
literature indicated that 40% of care home residents would be likely to be prescribed antibiotics over a
12-month period. This figure would enable the research team to fit a 95% CI to an AAD rate of 25%± 10%.
Interim analysis
A planned interim analysis was carried out evaluating data collected during the initial 3 months of the
study, together with 2 additional months of data for AAD follow-up. The interim analysis would provide
estimates of recruitment, antibiotic prescriptions and episodes of AAD. The duration and severity of AAD
were also assessed. These estimates would provide a scientific and medical justification for a trial of
probiotics to prevent/ameliorate AAD in care home residents, allow an understanding of the feasibility of
recruiting in this setting and give a firm basis for sample size calculation for the RCT.
Owing to the descriptive nature of the interim analysis, no adjustments were made to the final analyses to
correct for the fact that an interim analysis had been performed.
Progression/stopping criteria
Specific criteria related to recruitment, antibiotic prescribing and AAD were defined a priori. Specifically,
it was deemed infeasible to continue to a RCT if the percentage of residents recruited from those
approached was less than 60%. To justify a scientific and medical need for a RCT of probiotics in care
homes to reduce AAD, we felt that at least 27% of residents needed to have been prescribed at least one
course of antibiotics at the interim time point and at least 18% of prescriptions would have to result in at
least one episode of AAD. Should our AAD progression criteria not be met, we planned to also take the
severity of AAD into account when determining whether or not to progress to a trial.
Data analysis
Descriptive statistics were calculated for each care home type and overall using means (standard
deviations), medians [interquartile ranges (IQRs)] and proportions, as appropriate.
All incidence rates were calculated as per care home resident-year. Clustering of antibiotic prescriptions
and AAD by resident was explored and estimates were appropriately inflated.
The probability of residents being prescribed antibiotics was estimated by fitting a logistic regression
model, with results presented as odds ratios (ORs), 95% CIs, and p-values.
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We used logistic regression models to compare samples with and without antibiotic-resistant bacteria for
identified risk factors. Results are presented as ORs, 95% CIs and p-values.
To estimate the risk of developing AAD, a two-level logistic regression model was fitted with
stool-monitoring periods nested within care home residents. Results are presented as ORs, 95% CIs and
p-values. The time from antibiotic prescription to first episode of AAD was similarly estimated by fitting
a two-level Cox proportional hazards model. Results are presented as hazard ratios (HRs) with associated
95% CIs and p-values.
All regression models were entered in the following blocks: stool monitoring characteristics (for the AAD
models only), resident characteristics and care home characteristics. Explanatory variables were included if
they were associated with their outcome at the 20% level in a univariable analysis, with variables removed
from the final multivariable regression models if they were not significant at the 5% level and were of
marginal significance (p-value > 0.1) in the univariable analysis. All relevant modelling assumptions were
checked prior to reporting. Estimates from the regression models are presented from each stage of the
multivariable model, with corresponding univariable estimates.
The two-level Cox proportional hazards model was implemented using Stata version 10.0.18
(StataCorp LP, College Station, TX, USA). All other analyses were performed using IBM SPSS.
Substantial changes to study protocol
Over the course of the study a number of changes were made to the PAAD stage 1 protocol. Initially, the
intention was to include a sample of care homes of differing sizes from those with 20 beds or fewer to
those with 100 beds or more. However, there were very few nursing and dual-registered care homes with
20 beds or fewer in the South-East Wales region. As the most important factor in the care home sample
was care home type (nursing, residential and dual registered) it was decided to recruit three care homes of
each type regardless of size.
Several changes were made to improve recruitment and data collection. These included allowing verbal
consent (with witnesses present) to be provided if the resident or consultee was unable to sign the consent
form and enabling the research team to take copies of recruited residents’ MAR sheets at specific time
points to ensure the collection of valid concomitant medication data. It also came to light that many of the
residents and their consultees were frustrated that they were unable to give consent at the time they were
approached (i.e. directly after reading and digesting the information on the participant information sheet)
because the protocol stated a mandatory 24-hour ‘consideration’ time before they could join the study. As
a result of this the protocol was amended (with REC approval) to allow residents/consultees an opportunity
to provide consent at the time of their choosing.
Antibiotic prescribing and associated diarrhoea:
findings from a prospective observational cohort study
of care home residents
Care homes
Eleven care homes were recruited to the study. However, one withdrew before any residents were
recruited. Residents were therefore recruited from 10 care homes: four nursing, four residential and two
dual-registered homes. Nine homes were privately managed and one was managed by a LA. The median
number of beds was 39.5 (IQR 31.0–50.0) and the median number of residents at the time of recruitment
was 33.0 (IQR 28.0–50.0). The median number of staff working in a care home over a typical 24-hour
period was 16.0 (IQR 14.0–25.0), with 20.5% (n= 41) categorised as short-term staff members
(i.e. employed for less than 12 months) (Table 4 and Figure 3).
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
15
Participants
Three of the 389 residents (or consultees) approached were ineligible and 107 declined participation.
A total of 279 residents were therefore recruited (71.7%). Of those recruited, 19 withdrew, 16 (84%)
because they moved to a non-participating care home. Five of the 19 residents who withdrew from the
study also withdrew permission for data already collected to be used; therefore, our analyses are based on
a maximum of 274 residents (Figure 4). There were 81 hospitalisations reported during the study period,
with at least one hospitalisation reported for 58 (21.2%) residents (incidence rate of 0.14 hospitalisations
per resident-year, 95% CI 0.09 to 0.20 hospitalisations). In total, 64 residents died during the study
period. No deaths were deemed study related. Residents were observed for a median of 310 days
(IQR 230–364 days).
Care homes approached
(n = 22)
Care homes recruited from
(n = 10)
No contact made
(n = 10)
Care home declined
(n = 1)
Care homes agreed to take part
(n = 11)
Care home withdrew
prior to recruitment
(n = 1)
FIGURE 3 Care home flow diagram.
TABLE 4 Care home characteristics at study entry
Care home
type
Care home information Accommodation details Staffing details
Number
of care
homes
Privately
managed,
n (%)
Total number
of beds,
median (IQR)
Total number
of residents,
median (IQR)
Total number of
staff working in
the last 24 hours,
median (IQR)
Short-term
staff working
in the last
24 hours,a
median (IQR)
Nursing 4 4 (100.0) 36.0 (30.5–45.5) 30.0 (27.5– 41.0) 15.0 (13.0–20.5) 3.0 (1.5–4.5)
Residential 4 3 (75.0) 35.5 (28.0–39.5) 31.5 (26.5–37.0) 15.5 (13.0–16.5) 2.5 (1.0–3.5)
Dual
registered
2 2 (100.0) 70.0 (54.0–86.0) 66.5 (50.0–83.0) 37.0 (29.0–45.0) 10.0 (0.0–20.0)
Overall 10 9 (90.0) 39.5 (31.0–50.0) 33.0 (28.0–50.0) 16.0 (14.0–25.0) 2.5 (1.0–4.0)
a Employed for < 12 months.
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Descriptive data
Residents had a median age of 86 years (IQR 82–90 years), with 20.4% (n= 56) < 80 years old, 57.7%
(n= 158) between 80 and 90 years old and 21.9% (n= 60) older than 90 years. The majority of residents
(75.9%) were female. Overall, 28.5% (n= 78) had capacity to provide informed consent for themselves.
Few residents had any of the prespecified relevant serious medical conditions. At baseline, 7.7% (n= 21)
had faecal incontinence with loose stools, 1.8% (n= 5) had diarrhoea and 66.8% (n= 183) routinely
used incontinence pads. A ‘very fit to managing well’ classification was attributed to 13.5% (n= 37) of
residents, 51.1% (n= 140) were classed as ‘vulnerable to moderately frail’ and 35.4% (n= 97) as ‘severely
frail to terminally ill’. Nursing homes had more frail residents than residential homes. At baseline, 63.0%
(n= 172) were classified as having a low nutritional risk status, 14.3% (n= 39) as medium risk and 22.7%
(n= 62) as high risk. In the 4 weeks prior to recruitment, 6.9% (n= 19) had been admitted to hospital and
20.8% (n= 57) of residents were prescribed antibiotics (Table 5).
Residents in homes at study entry
(n = 397)
Residents approached
(n = 389)
Residents consented
(n = 279)
Final sample
(n = 274)
Resident died or withdrew
before being approached
(n = 8)
Included in antibiotic
prescription analysis
(n = 274)
Residents included in AAD
and time to first
AAD episode analyses
(n = 200)
Number of antibiotic
prescriptions, number of
residents prescribed
(n = 609, 202)
Resident missing date of
antibiotic prescription data
(n = 1)
Number of stool
monitoring periods
(n = 571)a
Resident missing stool
monitoring data
(n = 2)
Resident ineligible
(n = 3)
Resident declined
(n = 107)
Resident withdrew and
did not consent to us
using their data
(n = 5)
Included in time to first antibiotic
prescription analysis
(n = 273)
FIGURE 4 Resident flow diagram. a, Some prescriptions overlapped in time and so did the stool monitoring periods
in these instances.
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Interim analysis
At the interim time point, we had approached 363 care home residents and recruited 260, giving a
recruitment rate of 72% (95% CI 67% to 77%). We recorded at least one antibiotic prescription for
119 residents, giving an antibiotic prescribing rate of 46% (95% CI 40% to 52%). There were
152 antibiotic prescriptions recorded at the interim time point, 51 of which with a corresponding episode of
AAD, giving an AAD rate of 34% (95% CI 25% to 42%). As all criteria had been met, we were permitted
to begin designing a RCT of probiotics to prevent/ameliorate AAD in care home residents (Table 6).
Antibiotic prescriptions
There were 609 antibiotic prescriptions recorded over the study period, with 73.7% (n= 202) of residents
being prescribed at least one antibiotic course. We found an incidence of 2.16 antibiotic prescriptions per
care home resident-year (95% CI 1.90 to 2.46 prescriptions).
Antibiotics were prescribed for a median of 7.0 days (IQR 6.0–7.0 days), with 14.7% (n= 88) prescribed
for less than 5 days, 74.9% (n= 447) prescribed for between 5 and 7 days, 6.7% (n= 40) prescribed for
between 8 and 10 days and 3.7% (n= 22) prescribed for more than 10 days.
Antibiotics were most commonly prescribed for UTIs [29.3% (n= 177) of all antibiotic prescriptions],
followed by URTIs [28.8% (n= 174)], skin/connective/soft tissue infections [18.2% (n= 110)] and lower
respiratory tract infections (LRTIs) [18.0% (n= 109)]. The proportion of antibiotics prescribed for each
indication varied by care home type. For example, prescriptions for UTIs accounted for 25.4% (n= 71) of all
prescriptions in nursing homes, 43.5% (n= 70) in residential homes and 21.8% (n= 36) in dual-registered
homes (Figure 5). The five most commonly prescribed antibiotics were amoxicillin [30.6% (n= 186) of all
prescriptions], trimethoprim [12.7% (n= 77)], flucloxacillin [10.4% (n= 63)], nitrofurantoin [9.5% (n= 58)]
and co-amoxiclav [8.7% (n= 53)]. A wide range of antibiotics were prescribed for each indication (Figure 6).
TABLE 6 Summary of analysis relating to stopping/progression rules from stage 1 (observational study) to
stage 2 (RCT)
Outcome Stop if Estimate
Result
(proceed/stop)
Recruitment The proportion of residents recruited is
less than 60% of those approached
260/363= 72% (95% CI 67% to 77%) Proceed
Antibiotic
prescribing
The proportion of recruited residents
prescribed at least one course of
antibiotics is < 27%
119/260= 46% (95% CI 40% to 52%) Proceed
AAD The proportion of antibiotic prescriptions
(with follow-up data) resulting in at least
one episode of AAD is < 18%
51/152= 34% (95% CI 25% to 42%)a Proceed
Severe AADb The proportion of antibiotic prescriptions
resulting in at least one episode of AAD
< 18% and the proportion of AAD
episodes classed as severe is low
There were no episodes of AAD lasting
longer than 2 weeks. Of the 34 diagnostic
stool samples received and analysed, eight
(24%) were found to contain C. difficile.
There were no episodes of AAD that
resulted in hospitalisation or death
Proceed
a Presented as the raw proportion with CI adjusted for clustering of prescriptions within residents. The most conservative
estimate is presented here (removing episodes that correspond to residents who normally have loose stools and have
them either 3+ times or day or a frequency that was unknown).
b Severe AAD is defined as AAD that (any of the following): lasts for > 2 weeks, results in hospitalisation or death, is
attributed to C. difficile.
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The fluoroquinolone ciprofloxacin, previously implicated in CDAD, was prescribed relatively uncommonly,
accounting for 3.0% (n= 18) of all antibiotic prescriptions recorded during the study period. Prescriptions of
ciprofloxacin were primarily given for UTIs [44.4% (n= 8) of ciprofloxacin prescriptions] and skin/connective
or soft tissue infections [27.8% (n= 5)]. Ciprofloxacin was also prescribed for LRTIs in two cases, for
one UTI, for one gastrointestinal infection and also in one instance as prophylaxis.
While the total number of antibiotic prescriptions each month varied considerably (range 0.09–0.29
prescriptions and average 0.21 prescriptions per resident), there was no obvious marked seasonal
variation (Figure 7).
Compared with nursing home residents, those residents from dual-registered care homes had a
significantly lower chance of being prescribed antibiotics during the study period (OR 0.38, 95% CI 0.18 to
0.79; p= 0.009). The odds of being prescribed an antibiotic during the study period were 2.64 times
higher for residents who had been prescribed antibiotics in the 4 weeks before study entry (95% CI 1.17
to 5.99; p= 0.020). Exposure to antibiotics was similar in residents who were vulnerable to moderately frail
or severely frail to terminally ill and those who were very fit to managing well (Table 7).
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Antibiotic-associated diarrhoea
Three antibiotic prescriptions (from two residents) provided no corresponding stool monitoring data. From
the remaining 606 antibiotic prescriptions there were 571 stool monitoring periods, ranging between
1 and 11 weeks. The discrepancy between the number of prescriptions and monitoring periods arose
because residents could be prescribed multiple antibiotics in the same week (hence, there was only one
ongoing monitoring period). There were 447 unique episodes of AAD reported, with 43.5% (n= 87) of
residents who were prescribed antibiotics experiencing at least one episode of AAD during the study
period. There were 0.57 episodes of AAD per care home resident-year for those prescribed antibiotics
(95% CI 0.41 to 0.81 episodes).
After controlling for length of stool-monitoring period, the odds of developing AAD during a stool monitoring
period were more than twice as high in residents who were prescribed co-amoxiclav (OR compared with no
co-amoxiclav prescription 2.19, 95% CI 1.06 to 4.52; p= 0.033), with the first AAD episode also occurring
sooner (median time to first AAD episode for residents who were and were not prescribed co-amoxiclav was
23 days compared with 28 days, respectively; HR 2.08, 95% CI 1.18 to 3.66; p= 0.011). Time to first AAD
episode was also shorter for residents who routinely used incontinence pads than for residents who did not
(median 26 vs. 42 days, respectively; HR 2.54, 95% CI 1.26 to 5.13; p= 0.009). Compared with residents in
nursing homes, those in residential homes were significantly less likely to develop AAD during the study
period (OR 0.12, 95% CI 0.05 to 0.27; p < 0.001) (Table 8) and experienced a slower time to first AAD
episode (median for residents in residential homes 56 days, median for residents in nursing homes 21 days;
HR 0.14, 95% CI 0.06 to 0.32; p < 0.001) (Table 9 and Figure 8).
TABLE 7 Factors associated with being prescribed antibiotics during the study period (based on 274 care
home residents)
Variable
Univariable
Multivariable
Resident characteristics
With care home
characteristics
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Clinical frailty: very fit to
managing well
Reference category for clinical frailty
Clinical frailty: vulnerable to
moderately frail
2.14
(0.99 to 4.65)
0.054 2.15
(0.98 to 4.71)
0.057 1.88
(0.84 to 4.23)
0.127
Clinical frailty: severely frail to
terminally ill
1.58
(0.71 to 3.51)
0.263 1.67
(0.74 to 3.75)
0.218 1.33
(0.56 to 3.16)
0.525
Prescribed antibiotics 4 weeks
prior to study entry
2.56
(1.15 to 5.72)
0.022 2.55
(1.14 to 5.72)
0.023 2.64
(1.17 to 5.99)
0.020
Care home type: nursing Reference category for care home type
Care home type: residential 0.48
(0.23 to 0.99)
0.048 – – 0.49
(0.22 to 1.09)
0.080
Care home type: dual registered 0.39
(0.19 to 0.79)
0.009 – – 0.38
(0.18 to 0.79)
0.009
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TABLE 8 Factors associated with developing AAD (based on 571 stool monitoring periods nested within 200 care
home residents)
Variable
Univariable
Multivariable
Stool monitoring
period characteristics
With resident
characteristics
With care home
characteristics
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Stools monitored
for ≤ 4 weeks
Reference category for length of stool-monitoring period
Stools monitored
for 5–8 weeks
3.59
(2.01 to 6.41)
< 0.001 3.48
(1.95 to 6.23)
< 0.001 3.61
(1.99 to 6.55)
< 0.001 3.65
(1.96 to 6.82)
< 0.001
Stools monitored
for > 8 weeks
2.99
(1.80 to 4.97)
< 0.001 3.04
(1.82 to 5.08)
< 0.001 3.27
(1.94 to 5.52)
< 0.001 3.40
(1.96 to 5.89)
< 0.001
Prescribed
co-amoxiclav
2.31
(1.23 to 4.31)
0.009 2.30
(1.19 to 4.46)
0.014 2.05
(1.05 to 4.01)
0.035 2.19
(1.06 to 4.52)
0.033
Resident had
capacity to provide
informed consent
for study
0.56
(0.29 to 1.08)
0.084 0.72
(0.35 to 1.49)
0.374 0.76
(0.36 to 1.62)
0.472
Resident frequently
used incontinence
pads at study entry
2.84
(1.52 to 5.30)
0.001 2.59
(1.30 to 5.15)
0.007 1.90
(0.94 to 3.82)
0.073
Clinical frailty: very
fit to managing
well
Reference category for clinical frailty
Clinical frailty:
vulnerable to
moderately frail
2.38
(0.95 to 6.01)
0.066 2.43
(0.94 to 6.28)
0.067 1.69
(0.59 to 0.45)
0.328
Clinical frailty:
severely frail to
terminally ill
2.87
(1.10 to 7.44)
0.031 2.30
(0.83 to 6.37)
0.108 1.40
(0.43 to 4.56)
0.575
Care home
type: nursing
Reference category for care home type
Care home
type: residential
0.11
(0.05 to 0.24)
< 0.001 0.12
(0.05 to 0.27)
< 0.001
Care home type:
dual registered
0.69
(0.36 to 1.35)
0.278 0.60
(0.27 to 1.32)
0.199
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TABLE 9 Factors associated with time to first AAD episode (based on 571 stool monitoring periods nested within
200 care home residents)
Variable
Univariable
Multivariable
Stool monitoring
period characteristics
With resident
characteristics
With care home
characteristics
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Prescribed
co-amoxiclav
2.13
(1.20 to 3.78)
0.010 2.13
(1.20 to 3.78)
0.010 1.96
(1.11 to 3.47)
0.020 2.08
(1.18 to 3.66)
0.011
Resident
frequently used
incontinence
pads at
study entry
4.04
(2.04 to 7.99)
< 0.001 – – 3.80
(1.87 to 7.70)
< 0.001 2.54
(1.26 to 5.13)
0.009
Clinical frailty:
very fit to
managing well
Reference category for clinical frailty
Clinical frailty:
vulnerable to
moderately frail
4.60
(1.50 to 14.07)
0.007 – – 3.76
(1.19 to 11.85)
0.024 2.49
(0.78 to 7.94)
0.124
Clinical frailty:
severely frail to
terminally ill
4.58
(1.44 to 14.50)
0.010 – – 2.98
(0.91 to 9.78)
0.071 1.75
(0.50 to 6.09)
0.381
Care home
type: nursing
Reference category for care home type
Care home
type: residential
0.10
(0.05 to 0.23)
< 0.001 – – – – 0.14
(0.06 to 0.32)
< 0.001
Care home
type: dual
registered
0.80
(0.44 to 1.47)
0.476 – – – – 0.82
(0.43 to 1.57)
0.547
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FIGURE 8 Survival curves illustrating the association between care home type and time to first AAD episode.
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Clostridium difficile-associated diarrhoea
Of the 447 unique episodes of AAD, corresponding microbiological data from stool samples were available
for only 55. C. difficile was cultured from eight of the sample. C. difficile was also detected in a further five
stool samples taken after residents experienced loose stools (i.e. BSC type 5–7 stools) although the
frequency of stools did not meet our definition of AAD. The 13 samples were obtained from nine residents
in the same care home. In total, 12 samples were toxin B positive and there were nine different ribotypes
(005, 010, 014, 020, 026, 027, 106, 160 and 193). No ribotype was found in more than one resident
(Table 10).
Prevalence and risk factors for bowel carriage of
antibiotic-resistant bacteria and Clostridium difficile
in care home residents
Participant flow and recruitment
Of the 274 residents recruited, 80.7% (n= 221) provided a stool sample at study entry. Samples were
collected from all 10 participating care homes, with collection rates between care homes varying from
66.7% to 96.4% (Table 11). Participants who provided samples had a median age of 86.0 years
(IQR 82.0–90.0 years) and 78.3% (n= 173) were women. Over one-fifth (n= 49) had been prescribed
antibiotics in the 4 weeks prior to study entry and 7.2% (n= 16) of participants had been admitted to
hospital in this time frame. There were no statistically significant differences between participants who did
and did not provide samples (Table 12).
TABLE 10 Description of stool samples that contained C. difficile
Anonymised unique
participant ID Date sample taken Ribotype Toxin B
CDAD according to
our definition
1 2 March 2011 193 Positive Yes
1 8 May 2011 193 Positive Yes
2 10 May 2011 160 Positive Yes
3 24 April 2011 010 Negative No
4 4 January 2012 020 Positive Yes
5 12 April 2011 106 Positive Yes
5 24 April 2011 106 Positive Yes
6 7 June 2011 014 Positive No
6 20 July 2011 014 Positive No
7 23 April 2011 026 Positive Yes
7 23 April 2011 026 Positive Yes
8 30 April 2011 027 Positive No
9 12 June 2011 005 Positive No
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TABLE 12 Participant characteristics
Variable
Provided stool sample
data (N= 221)
Did not provide stool
sample data (N= 53) p-value
Age of resident (years), median (IQR) 86.0 (82.0–90.0) 85.0 (82.0–90.0) 0.915
Age of resident < 80 years, % (n/N) 21.7 (48/221) 15.1 (8/53) 0.283
Age of resident ≥ 80 years, % (n/N) 78.3 (173/221) 84.9 (45/53)
Gender (female), % (n/N) 78.3 (173/221) 66.0 (35/53) 0.061
Capacity to provide informed consent for study,
% (n/N)
28.1 (62/221) 30.2 (16/53) 0.757
Clinical frailty: very fit to managing well, % (n/N) 12.2 (27/221) 18.9 (10/53) 0.216
Clinical frailty: vulnerable to moderately frail, % (n/N) 50.2 (111/221) 54.7 (29/53)
Clinical frailty: severely frail to terminally ill, % (n/N) 37.6 (83/221) 26.4 (14/53)
MUST: low risk, % (n/N) 62.3 (137/220) 66.0 (35/53) 0.528
MUST medium risk, % (n/N) 15.5 (34/220) 9.4 (5/53)
MUST: high risk, % (n/N) 22.3 (49/220) 24.5 (13/53)
Prescribed antibiotics in last 4 weeks, % (n/N) 22.2 (49/221) 15.1 (8/53) 0.254
Admitted to hospital in last 4 weeks, % (n/N) 7.2 (16/221) 5.7 (3/53) 0.684
TABLE 11 Stool sample collection rates across care homes
Care home type Care home
Number of participants
recruited
Stool sample
collection rate, % (n)
Nursing A 21 61.9 (13)
B 42 83.3 (35)
D 11 90.9 (10)
I 13 69.2 (9)
Residential/EMI E 18 66.7 (12)
F 17 82.4 (14)
H 24 83.3 (20)
J 28 96.4 (27)
Dual registered C 59 74.6 (44)
G 41 90.2 (37)
Overall 274 80.7 (221)
EMI, elderly mentally infirm.
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Baseline data
Stool type
There was wide variation in the consistency of stool samples. Samples were most often described as a BSC
type 4, but over one-quarter of samples (n= 58) were described as a types 5–7 (Table 13).
Outcomes and estimates
Isolates cultured
In total, 478 isolates were cultured from the 221 collected stool samples (approximately 2.2 isolates
cultured per sample) (Table 14). The three most commonly cultured isolates were E. coli [88.2% (n= 195)
of samples], Enterococcus spp. (ex Thiercelin and Jouhaud 1903) Schleifer and Kilpper-Bälz 1984 [54.3%
(n= 120)] and Pseudomonas spp. Migula 1894 [25.3% (n= 56)]. The number of isolates cultured varied
among care homes, as did the number of different isolates found in their stool samples (Table 15).
In terms of total bacterial load, the total Columbia blood agar count was most commonly in the region
of 107–108 per 10-μl loop of faeces.
TABLE 13 Consistency of collected stool samples
Stool typea Samples, % (n)
1 5.4 (12)
2 14.0 (31)
3 14.9 (33)
4 37.6 (83)
5 15.4 (34)
6 8.6 (19)
7 2.3 (5)
Missing stool type 1.8 (4)
Overall 100.0 (221)
a 1, separate hard lumps; 2, sausage shaped but lumpy;
3, sausage but with cracks; 4, smooth and soft;
5, soft blobs; 6, mushy stool; 7, watery.
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TABLE 15 Description of isolates cultured by care home
Isolate
Care home type
OverallNursing Residential/EMI Dual registered
% (n)
Range
(%)a % (n)
Range
(%)a % (n)
Range
(%)a % (n)
Range
(%)a
E. coli 89.6
(60)
85.7–100.0 90.4
(66)
83.3–96.3 85.2
(69)
84.1–86.5 88.2
(195)
83.3–100.0
Enterococcus spp. 59.7
(40)
48.6–90.0 50.7
(37)
40.7–65.0 53.1
(43)
45.5–62.2 54.3
(120)
40.7–90.0
Pseudomonas spp. 22.4
(15)
10.0–44.4 23.3
(17)
10.0–33.3 29.6
(24)
22.7–37.8 25.3
(56)
10.0–44.4
Klebsiellab/
Enterobacterc/Serratiad
16.4
(11)
7.7–20.0 17.8
(13)
0.0–25.0 17.3
(14)
16.2–18.2 17.2
(38)
0.0–25.0
Other 16.4
(11)
7.7–22.9 12.3
(9)
0.0–25.0 18.5
(15)
16.2–20.5 15.8
(35)
0.0–25.0
Proteus spp. 14.9
(10)
0.0–23.1 11.0
(8)
7.1–20.0 19.8
(16)
15.9–24.3 15.4
(34)
0.0–24.3
Number of
samples/participants
100.0
(67)
100.0
(73)
100.0
(81)
100.0
(221)
EMI, elderly mentally infirm.
a Range of detection between care homes (lowest–highest %).
b Trevisan 1885.
c Hormaeche and Edwards 1960.
d Bizio 1823.
TABLE 14 Summary of isolates cultured by care home
Care home
type
Care
home
Number of
samples/participants
Total number of
isolates cultured
Average number
isolates/participant
Average number
isolates/participant
Nursing A 13 28 2.2 2.2
B 35 75 2.1
D 10 23 2.3
I 9 21 2.3
Residential/EMI E 12 24 2.0 2.1
F 14 27 1.9
H 20 44 2.2
J 27 55 2.0
Dual registered C 44 91 2.1 2.2
G 37 90 2.4
Overall 221 478 2.2 2.2
EMI, elderly mentally infirm.
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Antibiotic resistance
Organisms which were resistant to one or more of the tested antibiotics were found in 51.6% (n= 114)
of participants. Enterobacteriaceae resistant to ciprofloxacin were found in 47.1% (n= 104) of participants,
to gentamicin in 12.2% (n= 27), to third-generation cephalosporins in 10.9% (n= 24), to meropenem in
1.9% (n= 4) and to vancomycin in 1.4% (n= 3). There was wide variation in the proportion of participants
providing stool samples containing bacteria resistant to various antibiotics in different types of care
homes, with care home-level intracluster correlations (ICCs) ranging from 0.00 for meropenem and
vancomycin to 0.16 for gentamicin (Table 16). Of the four residents who provided samples containing
meropenem-resistant isolates, one was prescribed an antibiotic (amoxicillin) and none had been
hospitalised in the 4 weeks prior to study entry. Although resistance to ciprofloxacin, gentamicin and
third-generation cephalosporins was mainly found in E. coli [95.2% (n= 99), 63.0% (n= 17) and 73.9%
(n= 17), respectively], resistance to meropenem was exclusively found in Pseudomonas spp. (Figure 9).
Resistant bacterial load, expressed as a percentage of total bacterial load, varied between antibiotic
classes (Figure 10). For example, where isolates resistant to ciprofloxacin were found in stool samples,
ciprofloxacin-resistant isolates accounted for less than 1% of the total quantity of isolates cultured in
samples 12.8% of the time.
TABLE 16 Care home variation in the carriage of antibiotic-resistant bacteria, % (n)
Care home
type
Antibiotic/antibiotic class
Number of
samplesCiprofloxacin Gentamicin
Ceftazidime/cefotaxime
(third-generation
cephalosporins) Meropenem Vancomycin
Nursing 62.7 (42) 16.4 (11) 10.4 (7) 0.0 (0) 0.0 (0) 67
Residential 35.6 (26) 6.8 (5) 8.2 (6) 2.7 (2) 2.7 (2) 73
Dual
registered
44.4 (36) 13.6 (11) 13.6 (11) 2.5 (2) 1.2 (1) 81
Overall 47.1 (104) 12.2 (27) 10.9 (24) 1.8 (4) 1.4 (3) 221
Care
home ICCa
0.06 0.16 0.10 0.0 0.0 –
a The degree of clustering between care homes of the carriage of antibiotic-resistant bacteria expressed as the intracluster
correlation coefficient.
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Factors associated with carriage of antibiotic-resistant bacteria
The odds of participants carrying antibiotic-resistant bacteria in their stools significantly increased with age
(OR for 80 years or older 2.54, 95% CI 1.23 to 5.26; p= 0.012) and previous antibiotic use in the 4 weeks
prior to study entry (OR 2.21, 95% CI 1.11 to 4.43; p= 0.025). The odds of carrying antibiotic-resistant
bacteria were significantly lower for participants in residential homes than for those in nursing homes
(OR 0.44, 95% CI 0.21 to 0.91; p= 0.028). After controlling for the age of the resident, clinical frailty
status was not significantly associated with carriage of antibiotic-resistant bacteria (Table 17).
Prevalence of Clostridium difficile
Clostridium difficile was cultured in 7.2% (n= 16) of stool samples. The prevalence varied between care
homes, from no C. difficile detected in four care homes to C. difficile being detected in 19.4% (n= 7)
of samples from a single home.
One of the 16 samples from which C. difficile was cultured was toxin B negative, with the remaining 15
being toxin B positive. There were 11 different ribotypes (001, 002, 005, 015, 021, 027, 062, 103, 106,
160 and 193). In the majority of cases, ribotypes were unique to each home, with one instance of a
ribotype occurring within the same home twice (n= 106). The care home level ICC was 0.29 (Table 18).
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FIGURE 10 Percentage of resistant bacterial load by antibiotic class.
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TABLE 18 Prevalence of C. difficile in care homes
Care home type Care home
Number
of samples
C. difficile cultured,
% (n) Ribotypesa
Nursing A 13 15.4 (2) 015, 027
B 36 19.4 (7) 005, 027, 103, 106 (×2),
160, 193
D 10 0.0 (0) N/A
I 9 22.2 (2) 001, 005
Residential/EMI E 12 0.0 (0) N/A
F 14 0.0 (0) N/A
H 20 15.0 (3) 002, 005, 027
J 27 0.0 (0) N/A
Dual registered C 43 2.3 (1) 021
G 37 2.7 (1) 062
Overall 221 7.2 (16) 001, 002, 005 (×3), 015,
021, 027 (×3), 062, 103,
106 (×2), 160, 193
EMI, elderly mentally infirm; N/A, not applicable.
a Number in bracket indicates the ribotype frequency.
TABLE 17 Factors associated with carriage of antibiotic-resistant bacteria
Variable
Univariable
Multivariable
Resident characteristics
With care home
characteristics
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age of resident < 80 years Reference category for age of resident
Age of resident ≥ 80 years 2.94
(1.49 to 5.81)
0.002 2.67
(1.30 to 5.49)
0.007 2.54
(1.23 to 5.26)
0.012
Clinical frailty: very fit to
managing well
Reference category for clinical frailty
Clinical frailty: vulnerable to
moderately frail
2.48
(1.03 to 6.00)
0.044 2.11
(0.82 to 5.40)
0.122 1.78
(0.68 to 4.65)
0.243
Clinical frailty: severely frail to
terminally ill
2.21
(0.89 to 5.48)
0.089 1.74
(0.64 to 4.69)
0.275 1.35
(0.46 to 3.78)
0.614
Prescribed antibiotics 4 weeks
prior to study entry
2.07
(1.07 to 4.00)
0.031 2.10
(1.06 to 4.17)
0.034 2.13
(1.06 to 4.26)
0.033
Care home type: nursing Reference category for care home type
Care home type: residential 0.39
(0.20 to 0.77)
0.007 – – 0.44
(0.21 to 0.93)
0.030
Care home type: dual registered 0.57
(0.30 to 1.11)
0.099 – – 0.58
(0.29 to 1.16)
0.123
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Barriers and implementation issues identified and lessons learned
Research experience
Very few of the 10 sites had any experience of participating in research. Care homes are a unique research
environment since 24-hour care is provided to residents and, within any 1 day, care home staff have to
deal with many unpredictable daily events that need an immediate response. Careful consideration and a
flexible approach were needed to embed a study into this busy environment. We worked closely with our
lay representative and care home staff ahead of study commencement and throughout the study to ensure
implementation of PAAD stage 1 went as smoothly as possible and that all valuable and essential lessons
learned from PAAD stage 1 could be applied to PAAD stage 2. The most important factors we identified
for successfully delivering research of this kind in care home included the following.
Timing of approach to care homes
The time of year for approaching the care homes was critical, i.e. care homes are significantly affected by
winter pressures. Thus, training, embedding study procedures and commencing recruitment proved
difficult and, as a result, many care homes did not start recruitment until late winter or spring.
Approaching care homes and ensuring the study was up and running well ahead of the winter period was
pivotal when it came to setting up PAAD stage 2.
Care home set-up and training
A significant amount of time at the beginning was spent engaging with the care home staff and building
up their understanding, as well as setting up the processes, documentation and training for all staff. Initial
half-day training sessions were delivered and short (1 hour), tailored training sessions concentrating on
each staff member’s role and responsibility for the shift (day, night and weekend) were also designed.
Realistic time frames need to be set for approaching and bringing on board care homes. In addition, we
found that staggering care home set-up and ensuring recruitment has commenced before focusing on
another care home was likely to increase compliance with the Protocol and dedication of care home staff
to study procedures.
Staff engagement and motivation
Care home staff had little understanding of what it meant to carry out research; as a result they felt
overwhelmed by the tasks required of them, and not all staff understood the protocol. Half-day workshops
were also offered to care home staff to meet the study team and principal investigators (PIs) to discuss
issues and successes for the site, as well as focusing on topics such as how to improve recruitment or
resolve quality of data. Additional monetary and non-monetary incentives, such as providing opportunities
for continuing professional development (CPD) (e.g. GCP training) or personal incentives for staff working
on specific aspects of the protocol (e.g. gift vouchers), increased the level of interest in the study by junior
staff and return of completed stool-monitoring CRFs.
Communication
The shift patterns of care home staff meant that not all handover information was communicated well.
Key members of staff covering all shift patterns were required to discuss the PAAD study at each shift
change, and prompts were added to handover sheets as a reminder of this. Posters were provided for care
home notice boards to let relatives and residents know about the study and to ensure that the PAAD study
remained at the forefront of their staff members’ minds. Newsletters were also used to share information
between sites and to remind staff of key study procedures.
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Additional support for care homes
To ensure compliance with all study procedures, care homes required a lot of additional support. Within
PAAD stage 1, we introduced a research nurse in two care homes for 2.5 days per week and saw a huge
improvement in all areas of study procedures. We saw a dramatic increase in recruitment rates (all
residents were recruited within 3 weeks of site initiation), data collection quality and confidence, and
dedication of care home staff in delivering study procedures.
Summary
In summary, over 12 months the study team found that care homes are very different to other
environments in which general clinical research is carried out and that some of the issues raised are the
result of researchers’ lack of understanding in this new research environment rather than any naivety on
the part of care home staff. The study team has identified better ways of undertaking research in care
homes. Recommendations for future research conducted in these unique environments have been made
and include:
l At the design stage of the study, consult an ‘expert’ with experience of working in a care home.
l Allow plenty of time to initially approach care homes, set up the sites, recruit residents and undertake
the study.
l Bolster the confidence of care home staff.
l Ensure that processes are easy for staff to complete and where possible follow their own processes, so
as to not add to their workload.
l Identify study research leads among those working all shift patterns (weekdays, nights and weekends).
l Provide training to care home staff several times: 2–3 weeks before start of the study, before
recruitment, once the study begins and continuously after that point, with specific staff groups to
identify what is required of them.
l Embed own staff or employ research nurses in the care homes to collect information from residents
and carry out any sampling.
Summary of main findings
This prospective observational cohort study of 274 residents from 10 care homes across South Wales
found that antibiotics were prescribed at a rate of 2.16 per resident-year, with almost three-quarters of
residents prescribed at least one antibiotic course during the 16-month study period (median length of
follow-up 310 days). Residents were over two and a half times more likely to be prescribed antibiotics
during the study period if they had been prescribed antibiotics in the 4 weeks prior to study entry.
Residents were prescribed a wide range of antibiotics for each indication. The incidence of AAD in those
prescribed antibiotics was 0.57 episodes per resident-year, with 43.5% of residents prescribed antibiotics
experiencing at least one episode of AAD. Not all episodes of diarrhoea following antibiotic use can be
ascribed to antibiotics, and our study does not seek to demonstrate causality, merely association. CDAD
occurred in less than 15% of residents who developed AAD and for whom a stool sample was sent for
microbiological analysis. Although all CDAD episodes were found in residents from the same care home,
the unique ribotypes suggest that the episodes were not associated with an outbreak. Residents in nursing
homes were more likely to be prescribed antibiotics and experience AAD. Residents were more likely to
experience AAD if they had been prescribed co-amoxiclav or if they routinely used incontinence pads. The
majority of residents (80.7%) provided a stool sample at baseline. Analysis of these samples demonstrated
that there were high levels of carriage of antibiotic-resistant organisms in care home residents, particularly
of ciprofloxacin-resistant organisms. Although recent hospitalisation was not associated with carriage of
resistant organisms, recent antibiotic use was. Carriage of resistant organisms was significantly higher in
nursing homes than it was in residential homes, even after controlling for clinical frailty. C. difficile was
more common in nursing homes, but there was little suggestion of clustering by care home type.
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Chapter 3 Exploring ethical and practical
challenges of conducting research in care
home settings
Background
Both stages of the PAAD study were governed by laws and regulations concerning mental capacity to
provide consent to participate in research; PAAD stage 1 was covered by the MCA (2005)45 and, for those
residents who lacked capacity, personal consultees were able to provide agreement on behalf of the
resident for participation. PAAD stage 2 was covered by the Medicines for Human Use (Clinical Trials):
Regulations (2004)48 and consent would need to be given by a personal legal representative or a
professional legal representative of the participant.
The PAAD study presented two main challenges relating to consent. First, there were two categories of
residents who were eligible to join the PAAD study: those who had capacity and were able to consent to
participate for themselves and those who were unable to consent for themselves [lacked capacity under
the MCA (2005)45]. Trained senior care home staff/nursing staff or trained PAAD study research nurses
were responsible for assessing mental capacity by periodically checking that the information the resident
was given was understood by the resident. In addition, PAAD stage 2 would present novel challenges in
relation to advanced consent both for individuals who have capacity and for those who lack capacity.
Researchers49 have previously advocated an advanced consent procedure for individuals who might not be
able to give their consent to participate in a clinical trial at the time of randomisation. Advanced consent
may be particularly useful if the study intervention is administered in an emergency setting.50 For PAAD
stage 2, ‘advanced consent’ refers to a situation in which residents would be recruited into the study for a
12-month period, but randomised to receive a probiotic or placebo only if they were to be prescribed an
antibiotic (which may be anything from the next day to 365 days after giving consent). Indeed, it was
possible that some residents could enter PAAD stage 2 having capacity to consent, and then subsequently
lose capacity (either temporarily or permanently) because of an illness or deterioration in their health
during the 12 months that their consent to be part of PAAD stage 2 applied. The MCA (2005)45 makes
provisions for a personal consultee to advise on the continued participation of research subjects should
they lose capacity during a study,51,52 but this is in contrast to clinical trials of investigational medicinal
products (CTIMPs), when consent from an adult to participate in a trial remains valid, even after loss of
capacity, provided that the trial is not changed in any material way.
In PAAD stage 1, when residents lacked capacity, the resident’s consultee, typically a friend or relative who
visited the resident most often, was given information about the study, and asked for advice about
whether or not, in his or her view, the resident would have wanted to join the study.
In PAAD stage 2 (a CTIMP), in the event of residents lacking capacity, a legal representative would have
been required to give consent for the resident to participate in the trial. For the majority of residents who
lack capacity, a legal representative would typically be a friend or relative (a personal legal representative),
but could have been a professional legal representative. A professional legal representative should not be
connected with the conduct of the trial.
Owing to the PAAD study presenting novel challenges in relation to consent, we aimed to explore some of
the ethical and practical challenges of conducting these studies within the care home setting using
qualitative methods. The aim was to optimise an acceptable informed consent process in a vulnerable
population in preparation for PAAD stage 2, but also to inform the design of other similar studies.
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Design and aims
Specific aims of the qualitative exploration of practical and ethical issues
1. To collect data on the various merits and problems associated with a number of models of consent for
both PAAD stage 1 and PAAD stage 2 for residents who either have capacity or lack capacity.
2. To establish the views of residents, relatives, care home staff and GPs regarding participation in two
study designs (observational vs. CTIMP).
3. To establish the feasibility and acceptability of taking advance consent for research trial procedures
(as would be required in PAAD stage 2) in care home residents.
4. To establish views of relatives, residents and care home staff on participating in PAAD stage 1.
5. To establish care home staff views about the study training for staff, the requirements of the study and
its impact on the care home including the implications of potentially finding C. difficile in the care
home population.
We used qualitative research methods because this allowed us to explore in depth respondents’ views and
experiences, including topics that we were unable to predict in advance. We thought it important to
understand the views of a range of stakeholders and, so, our respondents included residents, relatives,
care home staff and GPs who have a responsibility for the general medical care of residents and who may
be asked to assess eligibility for research studies. We recruited through 10 care homes in South Wales,
which were participating in PAAD stage 1. Data collection was undertaken through a combination of
face-to face interviews with residents, relatives and GPs to facilitate in-depth reflection of respondents’
own involvement in the study and focus groups among care home staff to facilitate discussion about their
collective involvement in research.
A shorter version of this exploration of ethical and practical challenges of conducting research in care
home settings has previously appeared in the journal Trials.53
Participant recruitment
Recruitment of residents
Care home staff approached residents whom they felt had the mental capacity to consent to the
qualitative study. Residents were considered eligible to participate in the qualitative study even if they had
not given consent to participate in PAAD stage 1. A total of 14 residents consented to the study, all of
whom had consented to take part in PAAD stage 1. A research nurse conducted interviews with
informants in a private room in the care home, usually the resident’s bedroom. Interviews lasted between
9 and 54 minutes, with an average of 23 minutes. Participating residents were offered £25 in recognition
of their time.
Recruitment of relatives
Relatives of residents, four partners and 10 sons or daughters, were also invited by the care home staff to
be interviewed (all of whom had given advice as a personal consultee that their relative should be part of
PAAD stage 1) and all consented. Once again, interviews were conducted in a private room within the care
home by a research nurse. Interviews lasted between 12 and 31 minutes, with an average of 19 minutes.
Participating relatives were offered £25 in recognition of their time.
Recruitment of care home staff
Each care home was asked to nominate three members of staff who were most closely involved with the
PAAD study. Staff were invited to participate in a focus group that took place at a city-centre hotel. A total
of 19 staff from 10 care homes participated in the focus groups. Two focus groups were held, one with
senior staff (10 participants) and the other with junior staff (nine participants). Each group discussion lasted
approximately 90 minutes. The focus groups were facilitated by a research nurse and a qualitative
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researcher, both of whom were experienced in running focus groups. Neither had had prior contact with
the care home staff regarding the PAAD study. As care home staff were participating ‘off duty’, £25 was
offered to each participant. Lunch was provided, and travel expenses were reimbursed.
Recruitment of general practitioners
Senior care home staff were asked to name the main GP who attended residents within the care home.
Letters of invitation were sent to all 11 GPs named and two GPs responded. In view of this, the researchers
directly contacted 69 other GPs in the health board area to request an interview, which resulted in 10 GPs
agreeing to take part in face-to-face interviews. Three of these GPs were aligned to a care home participating
in PAAD stage 1, while seven were not but nevertheless attended residents in care homes. GP interviews
lasted between 20 and 35 minutes with an average of 27 minutes. GPs were offered £50 for their time.
Ethical permissions
South East Wales REC gave ethical approval for the qualitative study on 10 March 2011. All respondents were
provided with an information sheet about the purpose of the qualitative study and what was being asked of
them. All respondents signed a consent form immediately prior to the interview or focus group.
Data collection
An interview topic guide defined the main topics while allowing flexibility to pursue issues in more depth
as they emerged from the interviews and focus groups. Broad subject areas included participants’ views of
the consent processes that had been used for PAAD stage 1 and their experiences of participating in PAAD
stage 1, where appropriate. We collected data on the various merits and problems associated with a
number of models of consent that could be used for a trial that lasts a reasonably long period such as
12 months. Discussion also covered how consent discussions should take place, for example with a
witness, over the telephone, in person or by post. Respondents were asked what time frame they felt
advanced consent should cover. In addition, the researcher presented the respondent with a range of
hypothetical scenarios about taking advanced consent and asked the respondents to reflect on the
potential advantages and disadvantages (Box 1). They were also asked for their opinion on what should
BOX 1 Scenarios to facilitate the qualitative study interview discussions
Mrs Jones is an elderly resident in a care home participating in PAAD stage 2. Mrs Jones has been assessed by
one of the care home staff as not having capacity to consent to the PAAD study for herself. Staff in the care
home have approached her daughter, who lives in London and visits her mother at the home about once a
month, to ask if she would act as a personal legal representative on her mother’s behalf to give consent for her
to participate in a RCT of a probiotic versus a placebo.
What do you think might be some of the concerns of Mrs Jones’s daughter?
Mr Edwards is a resident in a care home and has been assessed as having capacity to consent himself for the
PAAD study stage 2. However, 6 months later he loses capacity. There is still a likelihood that he will need
antibiotics in the future.
Do you feel that Mr Edwards should still be part of the study?
What would your concerns be?
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happen should the resident lose (and potentially regain) capacity during a research trial. Data from the
focus groups and interviews were audio-recorded and transcribed verbatim.
Data analysis
Data were analysed using thematic analysis with an abductive approach (incorporating themes that had
been identified in advance and themes that were derived from the data).54 This approach involves
systematically coding data according to a thematic framework, which is developed iteratively. Researchers
met regularly to compare coding, discussing evidence for themes, and came to a consensus on the final
framework. The thematic framework was applied to the data using the coding software package
NVivo 8 (QSR International Pty Ltd, Doncaster, VIC, Australia). Interpretations were discussed between
members of the study team.
Interviews with residents
A total of 14 residents were interviewed. There were no major objections to being involved in research
generally and the PAAD study specifically, although some of the residents who were interviewed did not
remember that they had consented to the PAAD study or what it involved.
When asked why they agreed to take part in PAAD stage 1, residents gave a variety of reasons, including
wanting to help science, wanting to help others including their nursing home as diarrhoea is a problem for
them, because it was new and interesting and because they had no objections to participating. One
resident stated that he could not remember why he took part.
With regard to being in a study which used a method of advanced consent, the majority of residents
stated that they would be happy to be consented just once and it was not necessary to keep checking to
see if they still wanted to be involved:
Once at the beginning, I think that would be sufficient.
Resident 9
One resident stated that she thought that the researcher should check consent every 3 months to ensure
that she was well enough to participate. Moreover, another stated that there was no need to reconsent
somebody as long as there was an option to withdraw from the study.
I think there should be an escape route if you like.
Resident 12
Only two residents wanted someone to check more than once to see if they were still happy to be part of
the study. In this respect, residents seemed to be confusing giving their consent to participate with a
health professional checking their eligibility to be randomised.
Opinions on asking relatives to consent on behalf of residents were divided. The majority felt that the
relative would know the wishes of the resident and that it would be better to ask a relative than a
professional legal representative.
Oh yes, a relative, because I think they know you better and you understand them better.
Resident 10
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However, one resident stated that relatives should only be chosen if they were trustworthy and close to
the resident.
You don’t know, you see, whether they’re [the family] all that trustworthy.
Resident 9
Other residents felt that some relatives may not want to be bothered and may be too busy to help. Other
potential problems included the relative not agreeing with the research, difficulties with relatives who do
not live in the vicinity of the care home and some relatives being elderly and confused.
When discussing if a resident should continue to participate in the study if he or she lost mental capacity,
some suggested that the resident should be withdrawn from the study as the research would be too
demanding. Others, however, felt that the resident should continue to participate. Opinions were divided
on whether or not to give this decision to the relative.
I would say exceptionally, I would want to proceed with the survey [research study] because it’s
so important.
Resident 12
The people doing the research, I think they should really ask whoever is acting on their behalf.
Resident 13
Interviews with relatives
We interviewed 14 relatives. All 14 relatives we interviewed were happy for their resident relative to
participate in both PAAD stages 1 and 2. Many felt that, compared with other medical studies involving
invasive treatments, the PAAD study was comparatively harmless and they could see the potential benefits
to medicine and society. No major ethical concerns were spontaneously raised by relatives.
No relatives raised any concerns about C. difficile circulating within the home. A few relatives did raise
some queries about the probiotic including:
l Have the probiotics been tested on healthy populations and what was the outcome?
l How might the probiotics affect the resident if they are normally prone to constipation?
l Could the probiotics ‘cancel out’ the effect of the antibiotic?
l Could the probiotic affect any other medication that the resident takes?
l Would it matter if the resident had problems with swallowing?
Some relatives said they wanted more detail in the information sheet, while others reported that they were
sometimes overwhelmed with paperwork, and wanted the information in a simple and short format.
The relatives included in this sample were typically regular visitors at the homes. Many reported that they
found this helpful when being asked to be a personal consultee or personal legal representative. They felt
they knew the residents’ wishes well. They felt that relatives who visit irregularly, or who have little contact
with the home, would feel more anxious about being asked to take on the roles of personal consultee or
personal legal representative, partly because they would not be able to personally monitor the resident’s
condition and partly because there may be less trust established between care home staff and relatives.
I think they [residents] trust their relative to act on their behalf. I think a stranger coming in and trying
to talk them into doing something, they would be on their guard.
Relative 12
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I would say ‘no’ (to acting as a personal legal representative) if I were only here once a month to be
honest with you.
Relative 8
None of the 14 relatives we interviewed expressed any major concerns about PAAD stage 2 lasting
12 months. Generally, they understood why obtaining advanced consent was required. Two relatives
commented that 12 months can be an important time span with some residents’ health considerably
deteriorating in this time.
The sample of relatives we interviewed was split in terms of their views about whether or not the research
team needed to reconsent during the 12 months of PAAD stage 2. Three relatives felt that consent needed
to be checked at regular intervals during the study (typically every 3–6 months), although none of these
relatives stated that reconsent needed to be established in writing. Four relatives felt that it was not
necessary to reconsent but that the care home staff should continue to remind relatives informally that the
resident was still part of the PAAD study.
Well, if you’ve given consent, it might be nice to be reminded of it, you know.
Relative 13
Seven relatives stated that reconsenting during the 12 months was not required, as long as it was made
clear that residents and relatives had the right to withdraw from the study.
The sample of relatives was also split in relation to the question of what should happen if a resident has
given consent but then loses mental capacity during the course of the study. Five relatives felt that a
relative should be consulted about the resident’s continued participation.
You are going to want somebody to act on his behalf.
Relative 1
Four relatives felt that a relative should be informed as a matter of courtesy that the resident had given
their consent to participate in the study.
You know, maybe it would just be like an act of common courtesy.
Relative 14
Five relatives felt that the resident should continue in the study regardless of whether a relative is informed
or has given his or her consent. Many respondents acknowledged that this was a difficult issue. None
speculated about what might happen should a relative disagree with a resident’s continued participation.
Focus groups with care home staff
We conducted two focus groups with care home staff (one with senior staff and one with more junior
staff) with both groups comprising 19 care home staff.
Care home staff were generally very positive about the value of the PAAD study and their participation
therein. They reported that their original willingness to participate in the PAAD study arose from a belief
that older people were generally neglected in research, that antibiotics and diarrhoea were important
issues to address in this client group, that there were professional benefits for staff through increased
training and links to Cardiff University and that they were providing benefit to society.
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. . . because there isn’t a lot of research in elderly care, we just felt that it’d be nice to do something
that would be research based.
Focus group, junior staff
You need something to bring you up, bring you out, make sure that you’re still doing something with
your career, if you like, and we did, we sat down at one of our meetings for the qualified, sat down
talked about it, and felt it would be good for us, stimulate us.
Focus group, senior staff
However, having started the PAAD study most care home staff were surprised at the intensity and the
scale of the paperwork involved.
It’s also finding the time to do the consenting, and spend that extra bit of time to talk through: ‘cos
we’re getting them interested in it, you know, um well we did find that a bit hard, just getting the
time and really sit down, ‘cos with 54 residents, and getting the relatives in, a lot of them would come
after tea-time, which is a really busy time, you know around tea-time, after tea-time, a really busy
time, only two qualified on, quite hard then.
Focus group, senior staff
This situation was eased by NISCHR CRC research nurses preparing ‘resident packs’ which contained all
the relevant documents. NISCHR CRC research nurses had developed good relationships with care home
staff and their increasing involvement was considered to be extremely useful.
Many senior staff reported that consenting for PAAD stage 1 had been quite straightforward. However,
junior staff reported that taking consent was often difficult and very time-consuming. Senior staff were
considered to be better able to obtain consent from relatives than junior staff. There were specific
difficulties in obtaining consent in relation to (1) communicating with relatives who visited infrequently,
(2) locating a nominated consultee when no personal consultee (relative) could be found and (3) explaining
the study to residents with capacity, only for the resident to forget the purpose of the study shortly
afterwards. Some staff reported that relatives wanted simple explanations and were slightly put off by the
length of the information sheet. Consequently, staff reported that they had used the simplified information
sheets, which had been designed for residents, for relatives.
I think the way it will be written down will make a lot of difference whether people consent or not
because, you know, a lot of words can sometimes put people off, it’s a lot of terminology.
Focus group, junior staff
Staff reported that research procedures for PAAD stage 1 had been reasonable. Problems were identified
with some staff forgetting to complete CRF forms (particularly CRF 6), collecting stool samples (particularly
for residents who were semi-independent or from those who had loose stool and wore pads). The BSC
had not been used in all care homes prior to the PAAD study and it took some time to train all carers
about the detail of data collection required for the study.
Communication between staff was reported to be an issue. Although the PAAD study was sometimes
discussed during staff handover, it was frequently dropped from discussions because of competing
priorities. Staff stated that information about the PAAD study was not always appropriately cascaded
down to junior staff. Care homes took different approaches to reminding staff about the study, including
putting stickers on residents’ notes in the bedroom and putting BSCs on toilet doors.
Care home staff felt that PAAD stage 2 may give rise to more concerns among relatives who were
approached to act as personal legal representatives. During the focus groups, staff expressed confusion
over exactly what a ‘legal representative’ may mean (e.g. whether it meant that a power of attorney was
required), and how they should explain this to relatives. PAAD stage 2 was considered to be more
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complicated than PAAD stage 1 and more support was considered necessary for care home staff. Once the
concept of advanced consent was clearly explained, care home staff did not see advanced consent as an
issue. This was a model they were familiar with in relation to gaining advanced consent for photographs or
taking residents out on trips. However, a couple of staff raised the point that personal legal representatives
may themselves die or lose capacity over the period of 12 months. It was considered necessary to obtain
written consent only once, but staff thought that residents and relatives acting as personal legal
representatives should be reminded of their participation in the PAAD study a few times during the year.
It was felt that this could be adequately done through newsletters. Care home staff thought it reasonable
that they also remind residents and their relatives of their participation in the PAAD study at the point at
which the resident was randomised, as they would normally telephone the relative to inform them
that the resident had been seen by a GP and had been prescribed antibiotics. Should a personal legal
representative not be found, care home staff thought that social workers and or members of the
community psychiatric team could be approached to undertake the role of a nominated legal
representative. It was felt that solicitors would not get involved in health-related matters and advocates
were difficult to get hold of and tended not to get involved in research issues.
With the exception of only a couple of members of staff, all staff felt that it if a resident lost capacity
during PAAD stage 2, then a legal representative would need to be approached and consent taken. When
it was explained that (legally) this was not the case, some care home staff still insisted that they would
want to do this to ‘cover themselves’. At an absolute minimum they felt that they should inform
the relatives.
Well I think you’d have to reconsent with somebody that could give, well I feel I’d have to ask the next
of kin, if we could carry on. I’d really feel I’d have to do that.
Focus group, senior staff
There were only a few reports from care home staff that relatives had asked questions about C. difficile
circulating in the home. There were very few cases being reported of relatives bringing in probiotics for
residents. Care home staff did not feel that GPs were very aware of the PAAD study, despite having
received letters regarding their patients’ involvement in the study.
Interviews with general practitioners
We interviewed 10 GPs. Overall, no major ethical concerns were raised by GPs regarding PAAD stage 1 or
stage 2. The study was considered to have no harms, but it was felt that there was the potential for the
individual residents and the care home population to benefit.
Rates of C. difficile or harm that comes from it . . . I think you have to see it as something clinically
useful, as something that is going to make a clinical difference in the end.
GP 8
Some ethical tensions were raised, for example there may be a conflict of interest if GPs prescribe
antibiotics and are paid to enter a resident into the trial (in which case GPs may be more likely to prescribe
an antibiotic); the study may increase residents’ anxiety about taking antibiotics (being alerted that
antibiotics have side-effects); and the amount of information given to residents or relatives should not
be disproportionate to the harmless nature of the investigational medicinal product (IMP). One GP
commented that he had been informed by letter that a resident had given consent to the PAAD study.
This caused the GP concern because, in his view, this patient lacked the mental capacity to give consent.
Another commented that older adults often require time to consider a request to participate in a study,
but, when given time, they often forget what they were considering. One GP felt uncomfortable including
patients without capacity in a trial on the basis of another’s advice.
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I don’t feel comfortable about it at all because it, partly because I, I do feel that the patient should be
able to give informed consent if they are receiving something that is out of the ordinary from their
usual treatment.
GP 5
General practitioners felt that, although obtaining consent could be tricky at a practical level, most relatives
would be happy to be a personal consultee/personal legal representative. Some GPs also wished to remind
us that some relatives themselves are elderly and easily confused. A few GPs felt that some relatives
would not want to take on this responsibility.
All GPs thought that the advance consent arrangements for PAAD stage 2 were appropriate. Reconsenting
throughout the 12 months of PAAD stage 2 was generally not considered necessary and was regarded as
unnecessary paperwork. Reconsenting was considered even less necessary when it was explained that
residents would be randomised only once during the trial. However, some GPs did comment that it would
be appropriate, and a matter of courtesy, to verbally remind residents (or relatives, in cases where residents
do not have capacity) at 3- or 4-month intervals that they are still part of the PAAD study, and are free to
withdraw at any time. Other GPs suggested that at the time of randomisation the nurse/matron could
verbally check with the resident (or relative) that they are happy to be part of the study and this should be
recorded by the nurse in the resident’s notes.
One GP also raised the issue of how reconsenting during a 12-month period could be managed if trial
participants were to lose capacity during the study period.
I suppose the issue would be for someone who went from having capacity to losing capacity, and if
you’re going to reconsent, you’re going to have to reconsent everybody. Because it ought to
be consistent.
GP 1
When asked to reflect on their role in PAAD stage 2, GPs commented that they would want the process to
be as streamlined as possible, that they would want the research nurses/matrons to assess as many of the
eligibility criteria as possible, and they would want a clear reminder that the resident was consented into
the PAAD study. Many considered that out-of-hours cover would lead to problems with the system, and
being contacted by the care home/research nurse on a Monday morning to confirm eligibility following an
out-of-hours antibiotic prescription over the weekend would be considered a rather irritating request that
would receive a fairly short-shrift response compared with other priorities. They explained that they would
not want to undertake a separate care home visit that is not clinically indicated just to confirm eligibility to
participate in a research study.
Although PAAD stage 2 was generally felt to be a low-risk study, some GPs did reflect on the need to
ensure that systems were appropriately in place as (1) other researchers may follow similar systems for
other IMPs and (2) GPs were prescribing an IMP that was not available on the NHS.
When asked what would encourage them to participate in PAAD stage 2, GPs suggested money (although
note previously mentioned ethical tension regarding being paid for a study and for prescribing antibiotics),
having evidence of CPD for revalidation/appraisal, and being provided with some data for their practice
(or care home population) on AAD, outcomes, etc.
All GPs, with one exception, felt that a resident who lost mental capacity during PAAD stage 2 should be
allowed to continue in the study. Most GPs said that it would be appropriate to inform the next of kin
that the resident had consented to the study, but, with the exception of the one GP previously mentioned,
no GP suggested that a relative could override a resident’s wishes. The fact that residents could lose
(and regain) capacity during the study gave further weight to their arguments that residents did not need
to be reconsented during the 12 months of PAAD stage 2, as it would be impossible to reconsent those
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who had originally given consent for themselves and then lost capacity. They argued that, if the research
team were to reconsent residents, we would need to do that consistently across the study population,
regardless of whether or not they had lost capacity.
Summary of results
Residents, relatives, care home staff and GPs are generally supportive of older adults in care homes
participating in research studies. However, respondents were concerned about the best way of facilitating
this, and the amount of detail that participants can reasonably understand and retain from consent
discussions. Stakeholders were generally accepting of a model of advanced consent for studies including
drug trials and, although the majority did not believe that formal written reconsenting was required
through the trial period, they felt that participants should be reminded verbally of their involvement
throughout the trial. Some participants (particularly care home staff and relatives) felt that, if a care home
resident loses capacity during a trial, then his or her legal representative should be asked to give consent
for the resident’s continued participation.
A paper arising from this qualitative study has previously been published in the journal Trials.53
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Chapter 4 Stage 2: a randomised controlled trial
of probiotics to prevent antibiotic-associated
diarrhoea – study set-up and lessons learned
Introduction
Background
Results from PAAD stage 1 demonstrated sufficient grounds for progressing to stage 2: a double-blind RCT
to assess the clinical effectiveness of probiotics taken in conjunction with antibiotic treatment in reducing
the incidence of AAD. The process required to set up the RCT was lengthy and resource intensive, largely
because the study involved a CTIMP. The Medicines for Human Use (Clinical Trials): Regulations 200448
requires a favourable opinion from an ethics committee, and authorisation from the competent authority,
before a CTIMP can begin. The challenges encountered in obtaining statutory approvals, and in the
process of research governance in care homes, both unique to establishing a RCT in this research-naive
environment, resulted in significant delay. A number of strategies were employed to minimise the
impact of these issues. However, during this period of delay, new evidence emerged from the
probiotic lactobacilli and bifidobacteria in AAD and C. difficile diarrhoea in the elderly (PLACIDE) trial55
regarding the effectiveness of probiotics in reducing the incidence of AAD and CDAD in older hospital
inpatients. As a result, discussion took place with members of the Trial Management Group (TMG),
Trial Steering Committee (TSC) and the National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) funding programme (our funders), and the decision was made not to progress to the
recruitment phase of PAAD stage 2. Therefore, the planned objectives, to evaluate the clinical effectiveness
and cost-effectiveness of probiotics in conjunction with antibiotic treatment in reducing AAD, could not
be delivered.
Objectives
The primary objective was to assess the effect of probiotics, taken in conjunction with antibiotics, on the
incidence of AAD. This would be ascertained by comparing the proportion of residents in each arm who
experienced at least one episode of AAD during the 8 weeks following randomisation.
The PAAD study stage 2 also had a secondary objective: to assess the cost-effectiveness of probiotics for
AAD in care home residents. Total costs would be determined by multiplying the recorded data on
health-care resource use (including the cost of the probiotic) by relevant unit costs and assessing these
against quality-adjusted life-years generated from the European Quality of Life-5 Dimensions (EQ-5D)
data.56 Standard economic evaluation methods57 for dealing with skewed cost data, parameter uncertainty
and joint uncertainty in the cost-effectiveness ratio were to be applied.
Summary of research methods
Design and aims
The PAAD study stage 2 was planned to be a multicentre, double-blinded, placebo-controlled, two-arm,
individually randomised trial of the effectiveness of probiotics taken in conjunction with antibiotic
treatment in reducing incidence of AAD in care home residents.
The study design involved obtaining consent for the resident to be randomised to receive a probiotic or
matched placebo taken in conjunction with an antibiotic, should an oral antibiotic be prescribed by a
responsible clinician in the usual course of care at any point during the subsequent 12 months.
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and their relatives (where applicable) would be fully informed of the study using written materials and
posters in care homes, supplemented with verbal explanations. Consent was to be taken from residents
who were able and willing to provide this. In the event of cognitive impairment that limited ability to
provide fully informed consent, relatives and/or personal legal representatives would be approached to
provide consent on their behalf.
Consented, enrolled residents who were prescribed an oral antibiotic in the course of usual care at any
time during the 12 months after recruitment would be assessed by the GP to ensure that they remained
eligible to participate in the trial. If the resident was eligible, he or she would be individually randomised to
receive probiotics (VSL#3), or placebo, in addition to the antibiotic prescription. Residents would be
followed up by a research nurse for 8 weeks following randomisation (see Appendix 1).
The aim was to randomise 400 residents (200 per arm) from approximately 24 care homes. We planned to
recruit from care homes that had at least 50 residents. Smaller care homes would be considered if the
recruitment potential in these care homes was considered adequate. GPs serving the recruited care homes
would have played a pivotal role in recruitment and it was therefore essential to secure their commitment
to the study at the same time as the commitment of the care home (see Appendix 2).
Participants
Residents would be eligible for the study if they met all of the inclusion criteria and none of the exclusion
criteria. Inclusion criteria at consent were resident in a care home for 24 hours or more, with a minimum
planned period of residence of 1 month, and able to provide informed consent or have a representative
who could provide consent for inclusion. Residents met the exclusion criteria if they were severely
immunocompromised, had an artificial heart valve in situ, had a medical history of acute pancreatitis,
required nasojejunal feeding/nasogastric feeding, currently had a colostomy or did not have capacity and
were already receiving a probiotic.
Residents who had provided advanced consent and remained eligible for study medication would be
randomised to receive either the probiotic or the placebo once an antibiotic for an acute infection had
been prescribed by selection of the next sequentially numbered study medication pack.
Intervention
There were two planned intervention arms. The active arm was the nutritional supplement VSL#3
probiotic, which contained approximately 450 billion live lactic acid bacteria and bifidobacteria, together
with maltose and silicon dioxide. There were eight different strains of potentially beneficial bacteria:
Streptococcus thermophilus Orla-Jensen 1919, Bifidobacterium breve Reuter 1963, Bifidobacterium longum
Reuter 1963, Bifidobacterium infantis Reuter 1963, Lactobacillus acidophilus (Moro 1900) Hansen and
Mocquot 1970, Lactobacillus plantarum (Orla-Jensen 1919) Bergey et al. 1923, Lactobacillus paracasei
Collins et al. 1989 and Lactobacillus delbrueckii ssp. bulgaricus (Orla-Jensen 1919) Weiss et al. 1984.
The matching placebo arm of the study consisted of freeze-dried powder (4.4 g), matched for taste,
consistency, odour and colour.
The resident was to be given one sachet twice a day for 21 days. The sachet would be opened and the
contents stirred into 25–50ml of cold water or any non-fizzy drink or sprinkled onto cold food and
consumed immediately. The study medication would be given in between the antibiotic therapy and not in
conjunction with the antibiotic. The study medication would be commenced within 72 hours of the
resident being prescribed an antibiotic.
Outcomes
The primary outcome was the occurrence of at least one episode of AAD during the 8 weeks following
randomisation. AAD was defined as three or more loose stools (defined as 5–7 on the BSC) in a 24-hour
period following a period of normal stool consistency.
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Secondary outcomes included the occurrence of CDAD. This was defined as having a diagnostic stool
sample (following the occurrence of AAD) containing C. difficile toxin A or B. The duration, frequency and
recurrence of AAD were also to be measured, where the duration of AAD was defined as the total
number of consecutive 24-hour periods that a resident had AAD. The frequency of AAD was defined as
the number of episodes of AAD a resident experienced during the 8-week follow-up period. AAD episodes
were considered unique only if they were separated by a period of at least 3 days of ‘normal’ stool
consistency (defined as 1–4 on the BSC).
Other secondary outcome measures included:
1. Recovery from the illness that triggered the prescription of antibiotic treatment.
2. Adherence to the study intervention and antibiotic treatment.
3. Health-care resource use and unplanned hospitalisations, including all-cause and AAD related, during
the 8-week follow-up period.
Health-related QoL was also to be measured using the EQ-5D56 as a self-reported or proxy measure.
Adverse events included reported symptoms such as vomiting, abdominal pain, excessive flatulence,
bloating and skin rashes. All-cause mortality during the 8-week follow-up period would also be measured.
Sample size
A total of 400 residents (200 per arm) needed to be randomised in order to achieve 80% power, at the
5% level, to detect a 50% relative reduction in the incidence of AAD in those given probiotic alongside
antibiotic treatment, compared with placebo alongside antibiotic treatment. The sample size was
calculated using the interim data analysis from PAAD stage 1 assuming an AAD incidence of 25% in the
placebo arm. The sample size was adjusted for a 20% rate of withdrawal and loss to follow-up
(including death) using data from PAAD stage 1.
Taking into consideration the results from the interim analysis performed in PAAD stage 1 and a more
recent interim assessment of antibiotic prescribing and AAD (from first antibiotic prescription), assuming an
AAD incidence of 25% in the placebo arm, in order to randomise 400 residents, advanced consent was
required from at least 607 residents (assuming that 66% would be prescribed at least one course of
antibiotics during the 12-month monitoring period and subsequently randomised). Approximately
1214 residents would be approached in order to achieve this consent rate (assuming that only 50% will
provide consent). With an average of 60 residents per home, we needed to recruit from a minimum of
21 care homes. In order to allow for care home drop-out, more than anticipated withdrawals/drop-out/
declines and fewer than anticipated care homes, we aimed to recruit from 24 care homes.
Data collection
Data would be collected for 8 weeks following randomisation, to include a daily diary which records
symptoms and medications used and side-effects, a stool chart and QoL questionnaire (EQ-5D).
Data collection would be undertaken by care home staff, following training in completion of study-specific
data collection tools, supported by research nurses who would visit care homes regularly to assist with
recruitment and randomisation and study-specific procedures.
Analysis
For the primary analysis, a logistic regression model would be constructed with ‘AAD during the 8-week
follow-up’ (YES/NO) as the dependent variable and ‘study arm’ (probiotic/placebo) as an explanatory
variable. The analysis would be adjusted for the potential clustering of residents within care homes via
multilevel analysis, and potential, prespecified confounding/risk factors as specified in the statistical analysis
plan. The primary analysis was to be based on the intention-to-treat principle. In a similar way to the
primary analysis, a logistic regression model would be constructed for the secondary analysis, with
‘returned positive stool sample for C. difficile toxin A and B following AAD’ (YES/NO) as the dependent
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variable and ‘study arm’ (probiotic /placebo) as an explanatory variable, in order to investigate the effect of
probiotics on the development of CDAD during the 8-week follow-up period. In an analogous way to the
primary analysis, this analysis was to be adjusted for clustering (if present) and confounding factors.
Challenges encountered and strategies used
Ethics approval
The REC provides an independent review of research involving humans, and is required to ensure that
the research reaches the required ethical standards.58 The Medicines for Human Use (Clinical Trials):
Regulations 200448 require that those incapable of giving consent should be given special protection.
The REC must consider whether or not there is justification provided by the research team for involving
adults lacking capacity in the trial. An application for ethics approval was submitted to the South East
Wales REC Panel D. Ethics approval for the study was not granted initially, as the REC requested further
clarification from the research team on a number of issues including the remuneration to care homes for
taking part in the research, the potential recruitment of residents without mental capacity and also the
assessment of mental capacity.
Data obtained from PAAD stage 1 showed that the majority of eligible residents (69%) lacked capacity.
This evidence, together with the need for a representative sample population without bias, was provided
as support for the inclusion of residents without capacity to the REC. The MCA (2005)45 states that there is
a presumption that a person has mental capacity, unless there is concern to the contrary. If concerns were
raised about a resident’s capacity to consent to participate, an assessment of mental capacity would be
conducted initially by senior care home staff familiar with the resident. If the care home staff or researchers
were uncertain about a resident’s mental capacity, the research nurses trained and experienced in
assessment of mental capacity would conduct an assessment using a standardised template and record
the findings.
The REC required further justification for inclusion of residents without capacity from the research team in
order to meet the conditions set out in the Medicines for Human Use (Clinical Trials) Regulations 2004
Informed Consent in Clinical Trials Guidance.59 Preliminary findings available from the PAAD stage 1
showed that there were significant differences between the groups of participants with and without
capacity in terms of prescription rates for antibiotics, frailty scores, nutritional risk and rates of AAD. These
data were provided to the REC as evidence for the inclusion of residents without capacity as the
population most at risk of antibiotic treatment and the associated adverse consequences and, therefore,
most likely to benefit from the intervention. Ethics approval was granted following this evidence.
The process for gaining REC approval for this trial took 4 months. In contrast, PAAD stage 1 received full
approval from a different REC within 1 month based on the initial application.
Understandably, the process required for ethics approval for a RCT in care home populations has been
more complex than in a non-CTIMP study based in the same population. Gaining approval took a longer
period of time, and significantly more evidence was required for the justification for including residents
without capacity.
Competent authority approval
The intervention that was planned to be used in the trial was a probiotic preparation (VSL#3) that is
commercially available to the general public as a food supplement. The research team presented evidence
that the manufacturers class the probiotic as a food supplement that is commercially available without
prescription and is low risk, and that its use within the trial was within its indication in the investigator
brochure. The Medicines and Healthcare products Regulatory Agency (MHRA) subsequently confirmed that
the trial was classified as a CTIMP and did require clinical trial authorisation (CTA).
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Before granting CTA, the MHRA requires proof that the whole manufacturing process has been carried out
in accordance with terms and conditions of a marketing authorisation (MA) for the product to ensure that
strict quality assurance is maintained throughout the process. A qualified person (QP) provides certification
for each batch of a medicinal product in accordance with good manufacturing practice. The product used
in this trial had a complex manufacturing and importation process before reaching the trial site. The
request for CTA was not initially accepted as the MHRA required further information regarding the MA;
however, the status of the product as an IMP was difficult to reconcile with its licenced manufacture and
production as a food supplement, despite being listed as a medicine in the British National Formulary.
The delays in MHRA approval and the contract impacted on labelling of the IMP and placebo and delayed
commencement of randomisation. This in turn had a knock-on effect on the start of enrolling residents
into the trial and obtaining consent, as it was undesirable to have a large gap between consent and
beginning the process of randomising residents should they be prescribed an antibiotic.
The classification as a CTIMP had a significant impact on the time to commencement of the trial. The
discrepancy between the statutory authorisations requirement for an IMP, and the absence of any such
documentation for the product used in the trial, had a significant impact on the continuation of the trial.
Research governance
Research governance in care homes is complex owing to their status as non-NHS institutions, the
ambiguous nature of the environment as both a public and a private space and the unique nature of the
setting where the community of residents must be considered as a whole in addition to each individual.60
The contractual and financial arrangements of the resident as self-funding, LA funded or a mix of both
will have an impact on research governance. This is further complicated by whether the care provider is a
commercial or non-commercial organisation (independent sector, voluntary sector or LA owned). This
means that residents may be covered by different research governance processes, and may change from
one process to another if their individual circumstances change.
As non-NHS institutions, there was a lack of clarity regarding where responsibility for research governance
lay for the care homes involved in this trial in Wales. This was further clouded by the classification of the
trial as a CTIMP and the fact that, although care homes would be the main sites, GP practices would also
be sites and are NHS organisations. This resulted in delays with gaining site-specific assessment (SSA), as
non-NHS SSAs are carried out by the REC; however, the responsibility for NHS SSAs lies with NHS research
and development departments. The trial also covered a number of NHS trusts and LAs’ social service
departments. Each of these organisations conducted their own approvals process.
The question of who would be acting as PI for the trial sites also raised difficulties. The structure varies
between each individual care home; however, those with the most responsibility on a day-to-day basis are
care home managers. Care home managers usually have a nursing background, but some are not
registered health-care professionals and have a managerial background.
The regulations governing CTIMPs conducted at more than one site define ‘investigator’ as the ‘authorised
health professional’ responsible for the conduct of that trial at a trial site and, if the trial is conducted by a
team of health professionals at a site, the investigator is the leader responsible for that team. The
regulations define health professional as a doctor, dentist, nurse or pharmacist. The MHRA advised that
only care home managers who fulfilled these criteria would be eligible to act as investigator for the trial. It
also highlighted that GCP guidelines state that each individual involved in conducting a trial shall be
qualified by education, training and experience to perform his or her tasks. Although GCP training and
extensive study-specific training was provided to care home managers acting as PI for the site, there was
almost no prior research experience among this group. Extensive training and support is required by those
with responsibility as PI in research-naive care homes.
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Research governance in care homes lacks clarity. The process will differ between care homes, care home
residents, LAs and regions. Where care homes are participating in trials, particularly those involving IMP
and both NHS and non-NHS sites, the process for identifying responsibility for research governance is
problematic and resource intensive.
General practitioner recruitment
There is no standardised model of health-care provision for residents in care homes. Individual care homes
have individual policies regarding provision of GP services. This may encourage residents to register
with a ‘preferred practice’ that provides health care for a large number of residents at the home, or
encourage them to remain with their existing GP when moving into the home. A number of factors may
influence this, including geographical location (rural or urban), relationship with local GP practices and
financial arrangements.
The trial was designed to minimise the involvement of residents’ GPs because of experience from the
observational study and feedback from GPs involved in a qualitative study that investigated the consent
process for the RCT in PAAD stage 1. GPs had concerns about the impact on their workload if they were
required to check eligibility for care home residents and preferred a streamlined approach which minimised
their role. The study protocol stated that a research nurse would assess eligibility for the trial and the
responsible clinician at the resident’s GP practice would provide final approval for the resident’s inclusion.
However, recruiting GP practices whose patients were resident in participating care homes proved
challenging because of difficulties in arranging meetings with the busy clinicians and their reluctance to
commit to this responsibility. If care homes had residents registered with a number of GP practices,
agreement to participate had to be sought from a number of partners from each practice.
The practical difficulties experienced when seeking agreement to participate from GP practices, and the
requirements for each practice to be a trial site in terms of GCP training and study-specific training for
each GP, proved to be a major barrier to conducting the trial. Advice was sought from the MHRA in an
effort to further minimise the role of the resident’s GP. Clarification was sought as to whether or not a
registered nurse could confirm eligibility by accessing care home records for the resident or, where
required, their medical notes held by the GP. The MHRA’s response was explicit that the decision whether
or not a subject is eligible for entry into a clinical trial is considered to be a medical decision and, therefore,
must be made by a medically qualified doctor.
A strategy for communicating with GPs was developed to minimise the burden on them. This included the
availability of online GCP training along with drawing up a letter of agreement in place of a more
comprehensive practice agreement.
Care home recruitment
The RCT initially involved approaching 32 care homes. Five agreed to participate, with a number of other
homes expressing interest awaiting further follow-up of the interest to participate. Twenty care homes
declined to participate, four of these at a care home company group meeting. Reasons given for declining
were involvement in other studies (n= 2), concerns regarding residents’ suitability for research as a result
of their cognitive impairment (n= 1) and workload (n= 1). Twelve care homes gave no reason for
declining. It is unclear if there are any differences between homes by category (nursing vs. residential) in
willingness to participate. The dependency and care requirements of residents will vary between the two,
as will staffing levels and skill mix within the homes. Future studies in this area may need to consider
employing a GP clinical fellow to take this responsibility.
All participating care homes had a dual registration for nursing and residential care. There was a wide
variation in the ratio of residential to nursing beds, from 1 : 3 to 15 : 3. It is also unknown whether or not
the proportion of residents in the care home who have a cognitive disorder has an effect on agreement to
participate. All participating care homes had residents with and without mental capacity residing in
the home.
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Contacting care homes was a very time-consuming process. Consent for the care home to participate is
required from the care home manager and also, in some cases, the regional manager for the care home
group. A consensus of agreement from the care home staff is also required for the care home manager to
agree to participate. Consent in care homes has been described as a two-tiered process, where obtaining
consent at institutional/community level is required before progressing to consent from individuals.61 Care
home managers were generally positive about becoming involved in a research study and welcomed the
engagement with the researchers. The potential benefits of collaborating with a higher education institute,
and the opportunity to gain additional training and skills, were viewed as incentives to participate in the
study. Care home staff also welcomed the opportunity to examine current practice and the potential for
changing practice, where there was evidence to support this. This was seen in one participating care
home, with the adoption of BSC monitoring in a care home where there had previously been unsupported
attempts to introduce it by some care home staff. The process for recruiting 24 care homes was originally
expected to take 5 months but this was extended to 13 months as a result of the above difficulties.
Indemnity
Other issues that have arisen include the indemnity insurance requirements for care homes participating in
research, particularly CTIMP studies, as non-NHS sites. The REC confirmed that care homes were required
to provide evidence of adequate insurance indemnity. Indemnity is provided by the sponsor for research
activity and, therefore, the sponsor would be liable for any non-negligent harm resulting from activity
conducted in accordance with the protocol. However, any negligence on behalf of the site (for example
harm caused by protocol deviations such as giving an incorrect dose) would not be covered by the
sponsor’s insurance and, although the likelihood of a claim arising out of the trial is small, should be
covered by the site insurance. The REC was concerned that harm resulting from activity carried out in
contravention of the protocol would not be covered by existing policies as this would not form part of the
care home staff’s usual activities. The REC received advice from the Health Research Authority that, if the
activities did not form part of their routine professional practice, care homes should be asked to take out
an extension to cover research activity under their existing insurance.
Advice from research networks with experience in research in this setting [NIHR ENRICH (Enabling Research
in Care Homes) programme] suggested that, where a study involved an investigative product or an
intervention, indemnity would need to be checked on a case-by-case basis. Discussion was sought with a
participating care home’s broker whether research would be covered under existing insurance or whether
additional insurance was required. The broker confirmed that additional conditions would be required to
be met, such as evidence of study-specific training, prior to providing additional cover for research activity.
This requirement for each care home acting as a research site to provide indemnity for negligence on its
behalf had not previously been encountered by the sponsor and, therefore, was not detailed in the existing
contract with the care homes. A requirement for additional indemnity further impacted on the costs and
time required to set up a RCT in the care home sector and may impact on care homes agreeing
to participate.
Reasons for early termination of the trial
The extended time required for setting up the trial resulted in the anticipated date for first participant
recruitment being significantly delayed. Staff in the first care home were trained and ready to begin
recruitment 8 months after the initial anticipated date. However, CTA had not yet been granted and,
therefore, recruitment could not commence.
During this period of delay, the TMG became aware of emerging evidence that there was no longer
sufficient scientific evidence regarding the effectiveness of probiotics in reducing the incidence of AAD and
CDAD in older hospital inpatients.55 The PLACIDE study recommended that no further studies assessing
probiotics for AAD should be undertaken until further evidence is generated regarding which strains
maybe effective in reducing AAD (in vitro evidence).
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The TMG considered that the PLACIDE study population is likely to be very similar in terms of age and
frailty to a population recruited from care homes and that, although there were some differences in the
strains of probiotic organisms used in the PLACIDE study IMP and in VSL#3, there was also some overlap
(Box 2). The sample size of the PLACIDE study and the apparently tight CIs around their estimates
suggested that PAAD stage 2 would be unlikely to come to a different finding about the effect of
probiotics on the duration and severity of AAD.
Despite the differences between the two studies, the TMG considered that there was no longer equipoise
regarding the study question. However, it was agreed that continuing to build a research base within a
care home setting was vital.
This was considered to have a significant impact on the justification for commencing recruitment to PAAD
stage 2. Following consultation with the appropriate steering committees, and presentation to the HTA,
the decision was made that recruitment should not commence and the project should close.
During the close-down period, the study team continued the existing engagement with care homes to
establish a research base in the care home sector. This process was intended to optimise the value of
resources invested in research in this setting and aimed to support future research in the care homes
sector. Part of this process involved care home research priority setting exercises with stakeholders.
BOX 2 Summary of the main differences between the PLACIDE study and PAAD stage 2
1. Population:
i. older in PAAD
ii. likely to be more frail in PAAD
iii. more without capacity in PAAD
iv. sicker in PLACIDE.
2. Antibiotics prescribed:
i. more intravenous antibiotics in PLACIDE (although many would have been started on intravenous
antibiotics and switched to oral antibiotics), PAAD would be almost exclusively oral.
3. Probiotic used as intervention:
i. different way of giving probiotic – PAAD powder to dilute and drink or sprinkle on food, PLACIDE tablet
ii. different strains of bacteria in each probiotic (both contain a strain of Lactobacillus).
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Chapter 5 Stakeholder involvement
Introduction
The relationship between engagement of stakeholders in research planning and design, and the quality of
the research and its subsequent utilisation and impact on outcomes, has been discussed.62,63 The NIHR HTA
programme advocates involving service users in research and has developed an evidence-based approach,
which includes approaches to reducing barriers to meaningful participation.64 Involving patients, carers and
members of the public in the design and conduct of trials and studies improves the quality of the research
undertaken.65 There is a dearth of research conducted in care homes and with that comes a lack of
knowledge regarding how to best carry out research. Care home staff can be hesitant about getting
involved, as time and resources are sparse. Designing a research study that understood this busy and
demanding environment and the pressures the care home staff are under was essential.
The stakeholders
Throughout the study’s lifetime, a number of different stakeholders provided invaluable advice or took part
in interviews to enhance the research delivery. These included lay representatives; a director of seven care
homes; a former care home nurse and care home manager; care home staff; residents and their relatives
and professional representatives; NISCHR CRC research officers/nurses; and representatives from the NIHR
ENRICH programme.
Methods of stakeholder involvement
During the study development stage
The PAAD research team worked closely with a director of seven care homes in Wales. A number of
meetings were held with the primary aim of:
l obtaining more information on the structure of care homes
l gaining GP involvement and model of care delivery
l recruiting care homes
l estimating costs of conducting the research
l determining who could provide approval of research in care homes and finally conducting the study
l determining the additional resources required
l resolving consent issues
l determining prescription and treatment schedules
l assessing the feasibility of administering the probiotic and taking stool samples.
Valuable advice was provided which enhanced the final project design.
During the study
Lay representative on the Trial Management Group
We recruited a lay representative onto our TMG through Involving People. He was a qualified nurse who
had 40 years of activity in the voluntary/community sector, half of which was directly linked with elderly
care in independent care homes. He had experience of multidisciplinary teamworking and committee
activity. Most importantly, his stated passion was to bring evidence-based practice to care homes. During
the planning stage and the initial trial period we were able to use his experience to create the documents
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required to obtain the research data in a format easily understood by care home staff and to provide a
framework for inducting both NISCHR CRC research officers/nurses and care home staff into the task to be
undertaken. He was also pivotal at providing insight into the general issues the care home staff and
residents face every day, which over time became known as understanding ‘the rhythm of the care home’,
making the integration of our research activities into the care home smoother.
Lay representative on the Trial Steering Committee
A care home manager formed part of the PAAD study TSC and, therefore, commented on the protocol
and associated TSC documents and sent her approval ahead of study commencement. Unfortunately,
owing to work-related time commitments she was unable to attend many of the TSC meetings and
withdrew just before PAAD stage 2 was closed.
Workshops and regular teleconferences with care home staff
Two workshops were held with care home staff. These included breakout sessions to discuss challenges
and find solutions to topics such as (1) training and site set-up, (2) recruitment and consent, (3) practical
challenges and logistical issues and (4) ethical and practical issues of conducting research in care homes.
These provided valuable insight into the problems care homes were facing regarding embedding research
procedures into everyday running and provided solutions which could be rolled out in real time from which
the both the study and the staff could benefit from. Staff found these workshops incredible useful and
attendance was always very high.
Regular teleconferences were also set up to share experiences, discuss real-time issues and concerns and
ensure that both the study and specific study procedures remained in the forefront of the minds of care
home staff.
Focus groups with care home staff
As part of the qualitative study (described in Chapter 3), focus groups were conducted with all relevant
care home staff, which brought a deeper insight and understanding into conducting research in care
homes, the pressures care home staff are under in their everyday roles and, very importantly, their views
on the feasibility of taking consent in both PAAD stage 1 and PAAD stage 2.
Interviews with residents and their relatives
As part of the qualitative study (described in Chapter 3), interviews were conducted with both residents
and their relatives, who provided a useful insight into what it was like taking part in research, and in
particular their views on advanced consent and what was appropriate in this population were sought.
Interviews with general practices
As part of the qualitative study (described in Chapter 3), interviews were conducted with GPs who
regularly attended residents in care homes. These interviews provided valuable data about what GPs
considered to be important issues in relation to conducting research in care homes and the PAAD study
in particular.
National Institute for Social Care and Health Research – Clinical Research
Centre research officers and nurses
The NISCHR CRC research officers and nurses played a pivotal role supporting the care homes to deliver
the research. They therefore built up a unique understanding of the problems faced by the care home staff
in undertaking research. The NISCHR CRC research officers/nurses were able to provide an expert link
between the researchers and the care home staff. Throughout the course of the study and within the
workshops, in a breakout session, the NISCHR CRC staff provided the team with vital information
regarding how best to embed procedures into the care homes. Owing to the variation between care
homes, they were also able to develop personalised documentation and systems for the care homes to use
in order to maintain a record of who had been approached, recruited and followed up. They also provided
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insight into how effective the training sessions were, often identifying where more training was required,
as well as proposing better ways in which to motivate and engage with staff regarding the study.
Enabling Research in Care Homes
Owing to the lack of knowledge regarding how best to carry out research in this research-naive
environment, we attempted to bring together researchers working in this environment to share
experiences and develop effective procedures. An e-mail was distributed to all HTA chief investigators
working on a study in care homes and we were approached by the chief investigator of ENRICH. A
number of teleconferences and meetings were held with ENRICH colleagues. As a result, we provided
ENRICH with an article for its website on the challenges of conducting research in care homes and the
lessons we learned.66
Enabling Research in Care Homes provided us with advice regarding indemnity and research governance
within care homes, since this is one particular issue that currently does not seem to be resolved, as well as
a list of contacts for potential TSC members.
End of the study
Research priority setting by care homes
Background
There is a recognised need for the development of a more structured and evidence-based approach to
health-care provision for care homes.67 However, recruitment of frail, older people to research is a
complex68 and resource- and time-intensive process.44 This has resulted in widespread concern about
under-representation of older people from clinical trials69 and development for strategies to increase
participation of older people in clinical trials.70,71
Given the wide range of topics that require further investigation, and limited resources, there is a need for
stakeholders to participate in decisions regarding the prioritisation of topics for future research. The
importance of patient and public involvement in research has been the focus of a number of initiatives in
health and social care research,66,72 including the need for public involvement in identifying research
priorities.73 Research priority setting processes assist health-care researchers and policy-makers to effectively
target research that has the greatest potential public health benefit.74 Nominal group technique has been
used as a method of combining quantitative and qualitative data collection in a group setting to assist with
priority setting.75 The priority setting project formed part of the PAAD study activities; however, it was also
an integral part of the continued engagement with care homes and other groups.
Objectives
The primary aim of the project was to establish a set of priorities for research in health care in care homes
within South-East Wales. It was anticipated that the project would focus on this locality, but would be of
relevance to the wider care home and research community. The process was informed by review of
existing evidence, the identification of emerging themes, and the involvement of relevant stakeholders to
reach an agreement on elicitation of research topics, and ordering of priorities.
The secondary aim was to identify research questions that could be developed as proposals to research
commissioning bodies to be considered for funding.
The tertiary aim was to establish a collaborative group to continue developing the platform for research in
care homes established during the PAAD study. This would continue to support future research in care
homes and maintain engagement of stakeholders.
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Methods
Overview Participatory research techniques were utilised to achieve the aims of the project.
A working group was formed to develop and conduct the project. The process was supported by an
information-gathering and validation exercise, including a literature review. Emerging themes were
elicited from the participants and consensus methods were then used to prioritise these themes and
develop research questions around them.
Participation Stakeholders were identified and invited to participate in the process with regard to their
interest and involvement in research in care homes. These included care home staff, both senior and junior
grades, from care homes involved in PAAD stages 1 and 2 and other care homes who responded to
information flyers distributed by post. Each member was asked to consult with the wider group of care
home staff that he or she was representing. Participants were invited to attend a workshop event that was
held in a conference facility and facilitated by members of the PAAD study team.
Identification of priorities Following a general discussion of issues related to conducting research in care
homes, individuals were invited to identify and write a list of three areas of their work in care homes that
they felt would most be helped by research. The facilitators worked with the participants to form these
ideas into research questions. These were shared with the group and collated into a list. A number of
topics were also generated from discussion with the researchers and were included in the list of ideas
elicited. The list of topics was discussed and the researchers checked with the participants that these
represented their initial ideas.
Consensus on ordering of priorities A priority-setting exercise was conducted with participants to
determine, weigh and rank the results generated. Agreement on priorities was achieved through nominal
group technique work to order the priorities by means of scoring the research questions. Participants were
asked to identify the six topics which were ranked as the most important to them and to allocate them
scores from most important to the least important.
Owing to difficulties experienced by care homes in making staff available to attend a workshop, a number
of participants who were unable to attend the workshop were subsequently invited to rank the topics that
had been generated at the event via a postal survey. The survey was addressed to the named participant
or manager of the care home. The topics remained in the order in which they had been generated and did
not contain details of scores generated during the workshop. They were asked to score the six topics on
the list that they felt were the most important from the most important to the least important of their
chosen six topics. A stamped addressed envelope was provided and responses could be anonymous.
Results
Seven participants agreed to attend the workshop; however, owing to a number of unforeseen
circumstances, five were subsequently unable to attend on the day of the workshop. Participants attending
the event were two qualified nurses from dual-registered care homes in South Wales who were involved
in the day-to-day care of residents and had responsibility for supervising a team of care assistants and
nurses. One participant had been involved in PAAD stage 1 while employed at another care home and was
currently employed by a care home that had agreed to participate in stage 2. The other participant had
not previously participated in the PAAD study and did not have experience of participating in research, but
was employed at a care home that had agreed to participate in stage 2.
A total of 23 topics were identified at the workshop event, which included a spectrum of service delivery
themes and more specific health-related questions (see Appendix 3). Participants at the workshop
experienced some difficulty deciding how to allocate scores to topics. Where they felt strongly about
two topics, and were unable to choose which to allocate the score to, they were asked to score them by
allocating the score to both.
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Six completed postal surveys were returned and all returned completed postal surveys were anonymous.
Three completed surveys had not been scored in accordance with the instructions: participants had either
rated every topic on a scale of importance or had marked only the six most important topics and had not
prioritised them. These were not included in the prioritisation scoring.
Three returned surveys were scored in accordance with the instructions and the method used at the
workshop (most important topic was allocated 6 points, through to 1 point for the least important of their
chosen topics). One of these participants, who had been unable to decide how to allocate scores, had also
allocated scores jointly to more than one topic, although not explicitly invited to do so. Where scores had
been jointly allocated, they were each given the same number of points. The scores allocated by survey
were combined with scores allocated at the workshop (see Appendix 4).
The highest priorities for care home research in rank ordering were:
1. How can communication between staff and hospitals be improved when residents move into and out
of hospitals? Can the prescribing and dispensing of medication process be improved to reduce wasted
time and resources? (19)
2. How can care home staff, particularly nursing staff, best be kept up to date with staff development/
evidence updates for nurses in care homes? (13)
3. What are the best methods of diagnosing UTIs and what methods can be used for collecting reliable
urine samples in female residents with cognitive impairments? (12)
4. How can the current multiple and complex care referral pathways be improved so as to reduce the long
waits and wasted resources? (Care appears to be organised around professional services rather than the
patient, are there ways to make the process person-centred?) (11)
5. What improvements can be made in access to dental care for residents? And how effective are
techniques to improve oral hygiene, such as use of suction/rinse toothbrushes? (11)
6. Are there ways UTIs can be prevented and how can UTIs be predicted? (10)
Discussion
There was some uniformity between scores allocated at the workshop and those subsequently allocated
by postal survey. The topics that were rated as ‘most important’ were predominantly related to service
provision and improvements, staff development and evidence-based practice and the diagnosis, prevention
and treatment of UTIs. The topics scored as the most important topic and the third most important topic
were also rated as important by those who incorrectly completed postal surveys, although none of these
rated the second highest scoring topic as important.
Limitations
Owing to the time and resources available for the project, only care home staff were approached to
participate in the priority setting. Participation was not invited from others stakeholders, such as GPs,
geriatricians, charities or interest groups, or residents and their relatives on this occasion. Invitations were
initially posted to care homes, and were subsequently followed up by a visit to the care home or a
telephone call to the manager or, if unavailable, their deputy. This contact was intended to gain feedback
from the care home regarding their participation in a research study and to discuss participation in the
priority setting exercise. Care home staff were generally positive about their research involvement and
expressed interest in setting research priorities in the care home sector.
Despite intensive attempts to encourage participation, care home staff experienced difficulty in attending
an off-site event because of existing commitments within the care home and unexpected events requiring
their presence. However, those that did attend valued the opportunity to have a voice in defining potential
future research.
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Generalisability
These results are from a small sample of nursing staff with managerial responsibilities from care homes in
South Wales who had previously participated in, or agreed to participate in, the PAAD study, or had
expressed interest in research in care homes. All those who participated had a pre-existing interest in
research, and a number of those had experience in conducting research. All were from medium to large
care homes, although they represented a range of care home providers (independently owned, national
care home groups and LA managed).
Conclusion
Procedures from one environment are not necessarily transferable to another. In the case of the PAAD
study, understanding the general rhythm of the care home and the pressures the staff were under on a
day-to-day basis was essential to the success of the study. Stakeholders from a number of environments
are required in order to fully gain a deep understanding of how to successfully design and conduct studies
in care homes. The PAAD study stakeholders made a significant contribution to the design and conduct of
a study being delivered in a research-naive environment. The care home staff valued the fact that they
were able to contribute to the way in which the research was conducted and became enthused with the
idea that research could become an everyday part of care home life and that evidence-based practice was
not just a term associated with hospitals. Continuing to develop and maintain a network of research active
care homes and researchers is imperative if care home research is going to succeed.
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Chapter 6 Discussion
Stage 1: the observational study
Introduction
The PAAD stage 1 prospective observational cohort study of 274 residents from 10 care homes across
South Wales found that antibiotics were prescribed at a rate of 2.16 per resident-year, with almost
three-quarters of residents prescribed at least one antibiotic course during the 16-month study period
(median length of follow-up 310 days). Residents were over 2.5 times more likely to be prescribed
antibiotics during the study period if they had been prescribed antibiotics in the 4 weeks prior to study
entry. Residents were prescribed a wide range of antibiotics for each indication. The incidence of AAD in
those prescribed antibiotics was 0.57 episodes per resident-year, with 43.5% of residents prescribed
antibiotics experiencing at least one episode of AAD. CDAD occurred in > 15% of residents who
developed AAD and for whom a stool sample was sent for microbiological analysis. Although all CDAD
episodes were found in residents from the same care home, the unique ribotypes suggest that the
episodes were not associated with an outbreak. Residents in nursing homes were more likely to be
prescribed antibiotics and experience AAD. The risk of AAD with prescriptions of co-amoxiclav was double
that associated with other antibiotics. Risk of AAD was also increased in those who routinely used
incontinence pads.
Analysis of stool samples taken at study entry showed that over half of residents carried organisms
resistant to antibiotics, with resistance to ciprofloxacin particularly high. The proportion of participants
carrying antibiotic-resistant organisms varied between different types of care homes. We found that, while
recent hospitalisation was not associated with carriage of resistant organisms, recent antibiotic use was.
We also found that carriage of resistant organisms was significantly more likely for residents who were
prescribed antibiotics in the 4 weeks prior to study entry, and for those in nursing homes, even after
controlling for clinical frailty. C. difficile was more common in nursing homes, but there was little
suggestion of clustering of type by home.
Strengths and limitations of the prospective observational study
We conducted this study in a population and setting difficult to research,76,77 but we were able to estimate
the rates of participation, antibiotic prescription and AAD. Despite needing to obtain advice about resident
participation from consultees for the majority of participants in care homes, the recruitment target was
achieved in PAAD stage 1. This study can be considered to have a low risk of bias because of relatively
high inclusion rates in each care home and relatively complete follow-up data.78 Although every effort was
made to maintain the validity of the antibiotic and stool data, it is possible that this was not always
achieved. Prescriptions during periods of hospitalisation were not transcribed onto study CRFs, so the
number of antibiotic prescriptions may have been under-reported. Antibiotic prescriptions that were not
recorded for the purpose of the study may also have resulted in a lack of stool data for the defined
follow-up period. It is, therefore, possible that we have underestimated the incidence of AAD. Residents
who were recorded as routinely experiencing three or more loose stools in a 24-hour period before
observations were started were not classed as experiencing AAD during the study. We assumed that if
stool data were missing, AAD was unlikely to have occurred, but there may have been some episodes of
AAD that were not recorded. Our approach has, therefore, provided a conservative lower bound of
estimated AAD in care homes. Although we found that residents in residential homes are significantly less
likely to experience AAD than those in nursing homes, this may be in part because of the increased
mobility, with associated less intense monitoring of residents’ stools. We also found that residents were
more likely to experience AAD if they routinely used incontinence pads. This may be a real effect, but
could reflect easier observation and reporting of loose stool types, or be an artefact as a result of stool and
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urine mixing in an incontinence pad. Not all episodes of diarrhoea following antibiotic use can be ascribed
to antibiotics and our study does not seek to demonstrate causality, merely association.
Strengths of the stool sample study include its prospective nature and that we were also able to obtain a
stool sample from residents who were asymptomatic or not acutely unwell.
Comparisons to existing research
Despite most residents lacking capacity to consent to inclusion in the study, a majority in each of the 10
homes were included and the population is representative of those now living in care homes in the UK.79,80
Residents were predominantly aged 80 years and above, frail and at high nutritional risk. Levels of
nutritional risk were similar to levels found in care homes in the 2011 Nutritional Screening Survey.81
Residential, nursing and dual-registered homes were included; nearly all were privately managed, and
some specialised in looking after the elderly mentally infirm. We found little seasonal variation in antibiotic
prescribing and AAD, consistent with the mandatory and voluntary surveillance data.17
Our estimate of antibiotic prescribing is consistent with an estimate obtained from a study conducted in
North Wales,82 where 203 antibiotic prescriptions were recorded over a 9-week period in 15 nursing
homes (giving an incidence rate of 2.3 antibiotic prescriptions per resident-year). A study conducted in
nursing homes in Sweden83 found a rate of 0.51 antibiotic prescriptions per resident-year.
Estimates of AAD range from virtually zero in low-risk groups to over 40% in those at higher risk, but
these estimates are derived from control groups in trials of interventions for AAD, and not prospective
observational studies such as ours.42
Carriage of third-generation cephalosporin resistance was higher than in published rates for urinary isolates
in Wales (5%), despite the overall reduction in cephalosporin use that has been achieved between
2006–11,33 supporting arguments that the prevalence of extended-spectrum beta-lactamase-producing
bacteria is rising in Europe.34 Resistance to fluoroquinolones (ciprofloxacin) was also higher than previously
published rates. Fluoroquinolone resistance in community urinary coliforms in 2011 in Wales among adults
aged 80 years and over was 16.4%. Recent antibiotic use has been shown to be a key risk factor for
carriage of antibiotic-resistant organisms in previous studies.20,22–25,32,84,85 Previous antibiotic use has also
been shown to be a risk factor for the presence of extended-spectrum beta-lactamase-producing strain of
bacteria in long-term care.86 A dose–response association has been proposed by one study27 and multidrug
resistance has been linked to non-hospital antimicrobial consumption.29 Nursing home residence has been
previously shown to increase the risk of carriage of antibiotic-resistant organisms.30,41,84 Although we found
no association between recent hospitalisation and carriage of resistant organisms, an association was
found in a recent study investigating risk factors for drug-resistant pathogens in community-acquired and
health care-associated pneumonia.84 The sample of care home residents recruited for this aspect of the
research was representative of those recruited to the main cohort study. This group has been shown
elsewhere to be representative of residents living in care homes across the UK.79,80 The rate of C. difficile
infection in England was approximately 366.9 per 100,000 in 2011 for people aged over 65 years, while
the same rate was approximately 42.5 for those under 65 years of age.7 This indicates that C. difficile is
still an issue of concern for the specific age group, even though there was a 53% decrease in overall
numbers of reported cases between 2008 and 2011.8
The qualitative study on consent issues
Introduction
The qualitative study about consent and recruitment of care home residents to research found that
residents, relatives, care home staff and GPs are generally supportive of older adults in care homes
participating in research studies. However, respondents were concerned about the best way of facilitating
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this, and some subtle, but important, differences of opinion in how older adults should be recruited into
studies were apparent.
Limitations of the qualitative study on consent issues
Although the qualitative study reported here incorporates views from a wide range of stakeholders, we
acknowledge that our data may be biased. For example, we were able to interview only relatives who
were regular visitors to the care homes, residents who had capacity and care home staff who were
interested in participating in research. Although residents and relatives who had declined their consent to
participate in PAAD stage 1 were invited to participate in the qualitative study, only those residents and
relatives who had agreed to participate in PAAD stage 1 agreed to participate in the qualitative study. This
could have resulted in a biased sample that included more people who were more accepting of research.
We also do not know how many residents were approached by care home staff to participate and
declined to be interviewed, which may be a further source of potential bias. Furthermore, the GPs who
agreed to be interviewed may have been more knowledgeable of research ethics. We also acknowledge
that our respondents may not have been so supportive of research had the IMP been perceived as
more harmful.
Comparisons to existing research
Previous research has shown that an accurate and comprehensive patient information sheet is not enough
to ensure comprehension of the main issues.87 In our study this was evidenced by relatives struggling with
long and detailed information sheets which care home staff sometimes supplemented, or replaced, with
the short, graphically illustrated, information sheet which had been designed for residents. The data from
our qualitative study therefore confirm the importance of researchers and ethics committees making every
effort to improve the quality of consent discussions and consent documents, ensuring use of familiar
words and ideas, short sentences and paragraphs and routinely computing the reading ease of
information sheets.88
One important issue relates to the comprehension and retention of study information to achieve an
optimal level of informed consent. Residents and relatives were generally accepting of studies, which they
believed to be low risk, and answered important questions that were in the interests of care home
residents and the care home. Advanced consent was generally seen as acceptable in low-risk studies, and
there was consensus that if someone lost capacity during a trial that they had consented to participate in,
they should not necessarily be withdrawn from the trial unless the trial itself changed meaningfully.
The comprehension and retention of information by residents and their relatives becomes even more of a
challenge in a study which lasts a reasonably long period of time (12 months in the case of PAAD stage 2),
and in which some relatives, asked to act in the capacity of a personal consultee or a personal legal
representative, are themselves frail and at risk of becoming cognitively impaired. However, these specific
challenges, and challenges raised by other researchers, are not a reason to exclude older adults from
research. Although it is important not to underestimate the difficulties, recruitment strategies need to be
developed in order to maximise the involvement of frail older people while at the same time protecting
their right to decline participation. As participant information sheets are highly standardised, those who
recruit older adults to research studies will need training in methods of communication which promote
collaborative decision making and enable them to convey complex principles such as equipoise and
randomisation in appropriate language. Recruitment of older people, both with and without capacity,
to research studies can be complex but the awareness and integrity of the researcher is fundamental to
maintaining the principle of non-exploitation.68 Particular attention should be given to assessing visual and
auditory and mental status, compensating for communication and sensory deficits through the use of
innovative consent procedures such as pictorial information sheets and interactive tools that help
researchers to assess the potential participants’ understanding and retention of information relevant to
the study.89
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
61
The second main issue relates to the role of the personal consultee, or personal legal representative,
particularly when a research subject loses mental capacity during a research study or trial. Some relatives
expressed the view that the person to whom they were related was too elderly or frail and their
participation in research was inappropriate, despite the resident themselves having had capacity to decide
that they wanted to take part. If these relatives were to act as personal consultees or legal representatives
it is uncertain whether their advice or decision on inclusion would reliably reflect the resident’s wish rather
than their own. This was indeed raised as a concern by one resident. It is noteworthy also that 1 of the
10 GPs interviewed did not agree with including adults without capacity into any trial of a medicinal
product. It is perhaps worth exploring the extent of this attitude among a larger and broader sample of
GPs, health professionals, and care home staff, as if this belief is widely held it is likely that it will be a
barrier to improving recruitment of this under-represented group into research trials, despite their heavy
use of a wide range of health-care technologies.
In a study that lasts 12 months, it is likely that some care home residents who originally have capacity to
give consent may lose mental capacity. Furthermore, it is not unusual in such an age group for capacity
to be temporarily lost, for example as a result of delirium associated with a urinary tract or chest
infection.90 One important finding of our study was that many staff, relatives and residents felt that, if a
resident loses capacity during a clinical trial, then a legal representative must be consulted about that
resident’s continued participation in the study. This is in contrast to the majority of GPs, who believed that
this would not need to be the case. The MCA (2005)45 makes provision for a personal consultee to advise
on the continued participation of the research subject in studies, but this is in contrast to clinical trials of
medicinal products, when consent from an adult to participate in the trial remains valid, even after loss
of capacity, provided the trial is not significantly altered.
Although care home environments pose practical problems to researchers, our findings should inform
other research teams that care home residents, relatives and staff may be generally very supportive of
participating in research. Given that older people are the heaviest consumers of health and social care,
challenging ageist practices and attitudes in research is important if they are to gain maximum benefit
from advances in understanding and management. Ethics committees are also in a strong position to
influence research practice and to reduce unethical discrimination on the grounds of age or social
situation, by challenging researchers who continue to exclude these groups from research.
Research teams should consider using models of advanced consent for trials of interventions where there is
a high likelihood that participants may not have capacity at the point of randomisation. We would also
recommend that researchers who are conducting trials of medicinal products in care home settings ensure
that care home staff and residents are made aware that residents who have consented to a study have the
legal right to remain in the trial if they lose capacity during the study period, provided the person has not
indicated otherwise.48,49
Stage 2: the proposed randomised controlled trial of probiotics
to prevent antibiotic-associated diarrhoea in care
home residents
Main lessons learned from set up of Probiotics for Antibiotic-Associated
Diarrhoea study stage 2
The process of setting up a RCT in a care home setting has been more complex than the process of setting
up an observational study in the same setting and RCTs in other health-care settings. The additional
statutory approvals required for a CTIMP resulted in a longer and more resource-intensive process than
expected. Gaining ethics approval took a longer period of time than anticipated, and required significantly
more evidence for the justification for including residents without capacity, than in the case of the
observational study.
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The classification of the study, which involved a widely available food supplement, as a CTIMP had a
significant impact on the ability of the trial to proceed. The discrepancy between the statutory
authorisations required for a CTIMP and those needed for an IMP, and the absence of any such
documentation for a product generally characterised as a food supplement, had a significant impact on the
continuation of the trial. The implementation by the MHRA of a risk-adaptive approach is intended to
simplify the processes for initiating and conducting trials where a trial is considered to be in a low-risk
category. This subsequent change in approach may have reduced the difficulties experienced during the
setting up of the trial if it had been implemented prior to the initial application for approval.
There is a lack of clarity in research governance in care homes, particularly those involving IMP and both
NHS and non-NHS sites. The process for identifying responsibility for research governance is problematic
and resource intensive. Early consideration is required to ensure that sufficient indemnity is provided to
cover research activity at non-NHS sites not previously familiar with conducting research.
Recruitment of care homes, and GPs whose patients are resident in participating care homes, is a very
time-consuming process. Strategies can be developed to streamline the process and minimise the burden
anticipated by those who raised initial concerns about participating. However, the multiple layers of
permissions and agreement required at each level of the process before residents can be approached to
participate, remains an arduous process.
The requirement for additional support by researchers to care homes that are research-naive settings had
been identified during PAAD stage 1. However, the need to train care home staff conducting a CTIMP on
issues such as randomisation and administration of IMP further increased the level of training required. The
difficulties with care home staff availability for training required researchers to be flexible and imaginative
when designing and delivering training.
The need for a more structured and evidence-based approach to delivery of health care to care home
residents requires greater participation from this under-represented group. The challenges encountered
during this study, and the strategies used to minimise their impact, can be used by researchers to inform
the design and development of future research studies in care homes.
Priorities for future research in care homes
Those involved in the day-to-day care of residents in care homes consider, as a priority, research into
methods to improve communication between care home staff and hospitals when a resident is admitted
to or discharged from hospital. Care home staff described the problems associated with this; for example,
the written handovers that accompany a care home resident requiring hospital admission were frequently
mislaid and the discharge summary that is sent to the care home often did not contain adequate
information. This often resulted in gaps in a resident’s care and unnecessary delays. Strategies to
streamline the pharmacy processes are sought to avoid the duplication of medication dispensing, whereby
discharge medication is dispensed despite prefilled monitored-dose devices being used in the care home.
These issues impact on the care the resident receives; they may result in delayed treatment and in time and
other resources being wasted following up by telephone and making pharmacy visits.
Research to evaluate strategies to enhance staff development and update staff in relation to
evidence-based practice was also considered a priority. Care home staff, in particular nursing staff,
highlighted their lack of opportunity, as non-NHS professionals, to access updated evidence and research
findings. They considered that this was a major barrier to improving evidence-based care for this growing
population that has increasingly complex health-care needs.
Care home staff also viewed as important questions relating to the best methods of diagnosing UTIs in this
population, and reliable methods of urine sample collection in female residents with cognitive issues. They
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considered that UTIs had a significant impact on the physical, and often cognitive, well-being of care home
residents, with difficulties associated making accurate diagnosis and treatment leading to delayed or
inappropriate treatment. They also considered investigation into prevention and prediction of UTIs as
important, although this was not considered as high a priority.
A number of other, lesser, priorities for care home research have also been identified (see Appendix 3).
These included methods for improvements in care referral pathways for residents, improved access to
dental care and techniques to improve oral hygiene, safe minimum staffing levels and how hospital care
can be improved for residents.
Overall conclusion
Our study has demonstrated that residents of care homes are frequently prescribed antibiotics and
frequently experience diarrhoea following their antibiotic prescription. Our estimate is generally higher than
estimates derived from control groups of hospitalised patients in interventional studies. Stool samples were
only collected for a small proportion of AAD. CDAD was detected in about 15% of episodes in which we
had associated stool samples. Residents in nursing homes were most likely to be prescribed antibiotics and
experience AAD, but the size of the differences may in part be the result of the intensity of monitoring of
residents in these types of homes, rather than clinical differences in the residents. Clinicians should ensure
that their antibiotic prescribing is evidence based in this setting wherever possible. There is a paucity of
evidence to support antibiotic prescribing in care home residents. Further research is needed to investigate
the benefits of antibiotic treatment, and the development and evaluation of preventative strategies for
AAD in this setting.
Research staff should be mindful of research guidance and ensure that they have obtained an appropriate
level of informed consent without overwhelming the participant with unnecessary detail. For research
involving medicinal products, research staff should also be more explicit when recruiting that consent is still
valid should an older person lose capacity during a trial unless the individual expresses beforehand a wish
to be withdrawn in the event of loss of capacity and does not indicate objection or resistance after loss
of capacity.
Stakeholder involvement in care home research is important throughout the research process from study
design to recruitment of care homes and participants. Stakeholders’ insight into life in care homes and
valuable contribution to the design and conduct of a study being delivered in a research-naive
environment were essential to the success of the study.
Setting up and implementing research in care homes is more complex and time-consuming than may
immediately be apparent. Our trial of probiotics to prevent AAD was classified as a CTIMP and this had
far-reaching implications including the need for site-specific information forms for GPs, the logistical
problems associated with the need for GPs to confirm care home residents’ eligibility to be randomised,
even if the residents had already consented, and QP documentation for the probiotic. These problems
were solved, but recruitment data published just as we were about to start the trial led the study team, the
TSC and the funders to conclude that equipoise had shifted so far as to make continuing with the trial no
longer justified. However, future studies of what some might consider food supplements should establish
ahead of designing the study in detail whether or not the proposed trial will be classified as a CTIMP, as
the requirement for GPs to confirm eligibility for randomisation makes trials of acutely unwell care home
residents particularly challenging.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Acknowledgements
Contributions of authors
Professor Kerenza Hood (Professor of Medical Statistics, Director of the SEWTU) was a co-investigator,
led the study design and supervised the statistical analysis, had overall responsibility for the study
management and contributed to the study implementation and report submission.
Jacqui Nuttall (Senior Trial Manager) was a co-investigator, contributed to the study design, study
management and study implementation, and assisted in drafting the report and report submission.
David Gillespie (Research Associate) contributed to the study design, carried out all statistical analyses
and assisted in the drafting of the report and report submission.
Victoria Shepherd (Research Nurse) contributed to the study implementation and assisted in the drafting
of the report and report submission.
Dr Fiona Wood (Senior Lecturer) was a co-investigator of PAAD stage 1, contributed to the design, data
collection and analysis of qualitative data, and assisted in the drafting of the report and report submission.
Donna Duncan (Deputy Head of Nutrition and Dietetics) was a co-investigator, contributed to the study
design, recruited and trained care homes and contributed to the study implementation and
report submission.
Helen Stanton (Research Associate) contributed to the study design and acquisition of the data, and
assisted in the drafting of the report and report submission.
Aude Espinasse (Research Assistant) contributed to the study design and acquisition of the data, and
assisted in the drafting of the report and report submission.
Dr Mandy Wootton (Lead Scientist, Specialist Antimicrobial Chemotherapy Unit) contributed to the data
analysis and report submission.
Dr Aruna Acharjya (Clinical Trial Monitor) contributed to data collection, trial management, study
implementation and report submission.
Professor Stephen Allen (Professor of Paediatrics and International Health) was a co-investigator and
contributed to the study design and report submission.
Professor Antony Bayer (Professor of Clinical Gerontology) was a co-investigator and contributed to the
design and report submission.
Dr Ben Carter (Lecturer, Medical Statistics) was a co-investigator and contributed to the study design and
report submission.
Professor David Cohen (Professor of Health Economics) was a co-investigator and contributed to the
health economic evaluation and report submission.
Dr Nick Francis (Senior Clinical Research Fellow) contributed to the study design, study implementation
and report submission.
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
65
Dr Robin Howe (Consultant Microbiologist) was a co-investigator, contributed to the study design, data
analysis and report submission.
Dr Efi Mantzourani (Lecturer in Pharmacy Practice and Clinical Pharmacy) contributed to the study design
and assisted in the drafting of the report and report submission.
Dr Emma Thomas-Jones (Research Fellow) contributed to the management of the study and
report submission.
Alun Toghill (Involving People Representative) was a co-investigator and contributed to the study design
and report submission.
Professor Christopher C Butler (Professor of Primary Care Medicine) was the chief investigator, lead
applicant, study guarantor, and led the development of the research question, study design, study
implementation and report submission.
Contribution of others
National Institute for Social Care and Health Research – Clinical Research Centre collected data and
provided support to care homes.
Research support
Hayley Prout (research associate) recruited participants to the qualitative study and conducted all interviews
and one of the focus groups.
Administrative support
Mrs Judith Evans (research administrator), Mrs Sian Dawes and Mr Rhys Thomas.
Members of the Trial Management Group
Dr Meirion Evans, Dr Anthony Johansen, Dr Neil Wigglesworth, Ms Julia Townson and all those who
contributed to the study management.
Members of the Trial Steering Committee
Professor Peter Crome (chairperson), Dr Samuel Coenen, Mr Graham Tanner and Rachel Kemp.
Members of the independent Data Monitoring Committee
Dr Steven George, Professor Matthew Hickman, Dr Andrew Lovering and Professor John McLeod.
The Specialist Antimicrobial Chemotherapy Unit conducted the microbiological analysis.
Institutional support
We acknowledge with thanks the trial funders, the UK NIHR HTA. SEWTU is funded by the Welsh
Government through NISCHR and the authors gratefully acknowledge SEWTU’s contribution to the study.
Services and participants
We acknowledge, with thanks, all of the services, the residents, their representatives and the care home
staff who participated in the study.
We thank all those not otherwise mentioned above who have contributed to the PAAD study.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
Publications
Butler CC, Duncan D, Hood K. Does taking probiotics routinely with antibiotics prevent
antibiotic-associated diarrhoea? BMJ 2012;344:e682.
Wood F, Prout H, Bayer A, Duncan D, Nuttall J, Hood K, et al. Consent, including advanced consent, of
older adults to research in care homes: a qualitative study of stakeholders’ views. Trials 2013;4:247.
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
67

References
1. Laing and Buisson. Care of Elderly People: UK Market Survey 2012–13. London:
Laing and Buisson; 2013.
2. Bajekal M. Health Survey for England 2000: Care Homes and their Residents. London:
The Stationery Office; 2002.
3. Greenberg S, Fowles DG. A Profile of Older Americans: 2011. Washington, DC: US Department of
Health and Human Services, Administration on Aging; 2011.
4. Wittenberg R, Comas-Herrera A, Pickard L, Hancock R. Future demand for long-term care in the
UK. A summary of projections of long-term care finance for older people to 2051. Newsletter of
the Geneva Association of Insurance Economics 2004;11:2–4.
5. ECDC. Healthcare Associated Infections in European Long Term Care Facilities. Bulletin 3.
URL: https://halt.wiv-isp.be/report/Reports/HALT-1/HALT%20Report%20Pilot%20Survey%20Nov%
202009.pdf (accessed 16 July 2014).
6. Williams D. Prevalence Survey of Healthcare Associated Infections in Long Term Care Facilities (Halt
Study). Public Health Wales, 2012. URL: www2.nphs.wales.nhs.uk/WHAIPDocs.nsf/Public/
29B97D254270976280257A0D00426B0E/$file/Halt%20Report%20Wales.pdf?OpenElement
(accessed 16 July 2014).
7. van Buul L, van der Steen J, Veenhuizen R, Achterberg W, Schellevis F, Essink R, et al. Antibiotic
use and resistance in long term care facilities. J Am Med Dir Assoc 2012;13:568.e1–e13.
8. Warren J, Palumbo F, Fitterman L, Speedie S. Incidence and characteristics of antibiotic use in aged
nursing home patients. J Am Geriatr Soc 1991;39:963–72.
9. Nicolle L, Bentley D, Garibaldi R, Neuhaus E, Smith P. Antimicrobial use in long-term-care facilities.
SHEA long-term-care committee. Infect Control Hosp Epidemiol 2000;21:537–45. http://dx.doi.org/
10.1086/501798
10. Benoit SR, Nsa W, Richards CL, Bratzler DW, Shefer AM, Steele LM, et al. Factors associated with
antimicrobial use in nursing homes: a multilevel model. J Am Geriatr Soc 2008;56:2039–44.
http://dx.doi.org/10.1111/j.1532-5415.2008.01967.x
11. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334–9.
http://dx.doi.org/10.1056/NEJMcp011603
12. Antunes LCM, Han J, Ferreira RBR, Lolic P, Borchers CH, Finlay BB. Effect of antibiotic treatment on
the intestinal metabolome. Antimicrob Agents Chemother 2011;55:1494–503. http://dx.doi.org/
10.1128/AAC.01664-10
13. Fletcher KR, Cinalli M. Identification, optimal management, and infection control measures for
Clostridium difficile-associated disease in long-term care. Geriatr Nurs 2007;28:171–81.
http://dx.doi.org/10.1016/j.gerinurse.2007.02.003
14. Surawicz CM. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in
humans. Best Pract Res Clin Gastroenterol 2003;17:775–83. http://dx.doi.org/10.1016/S1521-6918
(03)00054-4
15. Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, et al. Antibiotic treatment for
Clostridium difficile-associated diarrhea in adults. Cochrane Database of Syst Rev
2011;9:CD004610.
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
69
16. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease.
Gut 2008;57:850–60.
17. Health Protection Agency. Voluntary Surveillance of Clostridium difficile Associated Disease in
England, Wales and Northern Ireland. 2012 URL: www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/
1317138039648 (accessed 6 March 2013).
18. Tam CT, Viviani L, Rodrigues LC, O’Brien SJ. The second study of Infectious Intestinal Disease (IID2):
increased rates of recurrent diarrhoea in individuals aged 65 years and above. BMC Public Health
2013;13:739. http://dx.doi.org/10.1186/1471-2458-13-739
19. Berrington AW. National Clostridium difficile standards group: report to the Department of Health.
J Hosp Infect 2004;56:1–38. http://dx.doi.org/10.1016/j.jhin.2003.10.016
20. Makris A, Gelone S. Clostridium difficile in the long-term care setting. J Am Med Dir Assoc
2007;8:290–9. http://dx.doi.org/10.1016/j.jamda.2007.01.098
21. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cummulative antibiotic exposures
over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:42–8.
http://dx.doi.org/10.1093/cid/cir301
22. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1–15.
http://dx.doi.org/10.1016/S0195-6701(98)90019-6
23. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium
difficile diarrhoea. J Hosp Infect 2003;54:243–5. http://dx.doi.org/10.1016/S0195-6701(03)
00088-4
24. Starr JM, Martin H, McCoubrey J, Gibson G, Poxton IR. Risk factors for Clostridium difficile
colonisation and toxin production. Age Ageing 2003;32:657–60. http://dx.doi.org/10.1093/
ageing/afg112
25. Pettersson E, Vernby A, Mölstad S, Lundborg CS. Infections and antibiotic prescribing in Swedish
nursing homes: a cross-sectional study. Scand J Infect Dis 2008;40:393–8. http://dx.doi.org/
10.1080/00365540701745279
26. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic
use in Europe and association with resistance: a cross-national database study. Lancet
2005;365:579–87. http://dx.doi.org/10.1016/S0140-6736(05)17907-0
27. Laffan AM, Bellantoni MF, Greenough WB, Zenilman JM. Burden of Clostridium difficile-associated
diarrhea in a long-term care facility. J Am Geriatr Soc 2006;54:1068–73. http://dx.doi.org/10.1111/
j.1532-5415.2006.00768.x
28. Kutty PK, Benoit SR, Woods CW, Sena AC, Naggie S, Frederick J, et al. Assessment of Clostridium
difficile-associated disease surveillance definitions, North Carolina, 2005. Infect Control Hosp
Epidemiol 2008;29:197–202. http://dx.doi.org/10.1086/528813
29. Chang HT, Krezolek D, Johnson S, Parada JP, Evans CT, Gerding DN. Onset of symptoms and time
to diagnosis of Clostridium difficile-associated disease following discharge from an acute care
hospital. Infect Control Hosp Epidemiol 2007;28:926–31. http://dx.doi.org/10.1086/519178
30. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a
potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among
long-term care facility residents. Clin Infect Dis 2007;45:992–8. http://dx.doi.org/10.1086/521854
31. Simor AE. Clostridium difficile diagnosis and management and prevention in long term care
facilities: a review. J Am Geriatr Soc 2010;58:1556–64. http://dx.doi.org/10.1111/j.1532-5415.
2010.02958.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
32. Havenaar R, Jos HJ, In’t Veld H. Probiotics: a general view. In Wood BJB, editor. The Lactic Acid
Bacteria Vol. 1. The Lactic Acid Bacteria in Health and Disease. New York, NY: Elsevier. pp. 151–70.
33. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with
Lactobacillus GG. Lancet 1987;2:1519. http://dx.doi.org/10.1016/S0140-6736(87)92646-8
34. Sullivan Å, Nord CE. The place of probiotics in human intestinal infections. Int J Antimicrob Agents
2002;20:313–19. http://dx.doi.org/10.1016/S0924-8579(02)00199-1
35. Allen SJ, Okoko B, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating infectious diarrhoea.
Cochrane Database of Syst Rev 2004;2:CD003048.
36. Ohland CL, MacNaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J
Physiol Gastrointest Liver Physiol 2010;298:G807–19. http://dx.doi.org/10.1152/ajpgi.00243.2009
37. Venugoplan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use.
Emerg Infect Dis. 2010;16:1661–5. http://dx.doi.org/10.3201/eid1611.100574
38. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the
prevention and treatment of antibiotic-associated diarrhoea: a systematic review and meta-analysis.
JAMA 2012;307:1959–69. http://dx.doi.org/10.1001/jama.2012.3507
39. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotics for the
prevention of Clostridium difficile associated diarrhoea in adults and children. Cochrane Database
Syst Rev 2013;5:CD006095.
40. Johnston B, Supina A, Vohra S. Probiotics for paediatric antibiotics-associated diarrhea: a
meta-analysis of randomized placebo-controlled trials. CMAJ 2006;175:377–83. http://dx.doi.org/
10.1503/cmaj.051603
41. Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, et al. Use of probiotic
Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind
placebo controlled trial. BMJ 2007;335:80. http://dx.doi.org/10.1136/bmj.39231.599815.55
42. Butler CC, Duncan D, Hood K. Does taking probiotics routinely with antibiotics prevent antibiotic
associated diarrhoea? BMJ 2012;344:e682. http://dx.doi.org/10.1136/bmj.e682
43. Mentes JC, Tripp-Reimer T. Barriers and facilitators in nursing home intervention research.
West J Nurs Res 2002;24:918–36. http://dx.doi.org/10.1177/019394502237702
44. Maas ML, Kelley LS, Park M, Specht JP. Issues in conducting research in nursing homes.
West J Nurs Res 2002;24:373–89. http://dx.doi.org/10.1177/01945902024004006
45. Great Britain. Mental Capacity Act 2005: Elizabeth II. Chapter 9. London: The Stationery
Office; 2005.
46. Elia M. Screening for Malnutrition: a Multidisciplinary Responsibility. Development and Use of the
‘Malnutrition Universal Screening Tool’ (‘MUST’) for Adults. MAG, a Standing Committee of
BAPEN. 2003. URL: www.bapen.org.uk/pdfs/must/must_exec_sum.pdf (accessed 15 July 2014).
47. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical
measure of fitness and frailty in elderly people. CMAJ 2005;173:489–95. http://dx.doi.org/10.1503/
cmaj.050051
48. Medicines for Human Use (Clinical Trials): Regulations 2004. URL: www.opsi.gov.uk/si/si2004/
20041031.htm (accessed 22 July 2014).
49. Rees E, Hardy J. Novel consent process for research in dying patients unable to give consent.
BMJ 2003;327:198. http://dx.doi.org/10.1136/bmj.327.7408.198
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
71
50. Royal College of Obstetricians and Gynaecologists. Obtaining Valid Consent to Participate in
Research while in Labour. Clinical Governance Advice No. 6a. URL: www.rcog.org.uk/files/
rcog-corp/CGAObtainingConsentResearchLabour0810.pdf (accessed 15 July 2014).
51. Great Britain. The Mental Capacity Act 2005 (Loss of Capacity during Research Project) (England)
Regulations 2007. London: The Stationery Office; 2007.
52. Great Britain. Mental Capacity Act 2005 (Loss of Capacity during Research Project) (Wales)
Regulations 2007. London: The Stationery Office; 2007.
53. Wood F, Prout H, Bayer A, Duncan D, Nuttall J, Hood K, et al. Consent, including advanced
consent, of older adults to research in care homes: a qualitative study of stakeholders’ views.
Trials 2013;14:247. http://dx.doi.org/10.1186/1745-6215-14-247
54. Green JNT. Qualitative Methods for Health Research. 2nd edn. London: Sage; 2004.
55. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifid
bacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in
older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet 2013;382:1249–57. http://dx.doi.org/10.1016/S0140-6736(13)61218-0
56. Brooks RG. Euroqol: the current state of play. Health Policy 1996;37:53. http://dx.doi.org/10.1016/
0168-8510(96)00822-6
57. Grey AM Clarke PM, Wolstenhole JL, Wordsworth S. Applied Methods of Cost-effectiveness
Analysis in Health Care. Oxford: Oxford University Press; 2011.
58. Department of Health (DH). Research Governance Framework for Health and Social Care. 2nd edn.
London: DH; 2005.
59. National Research Ethics Service Medicines for Human Use (Clinical Trials) Regulations Informed
Consent in Clinical Trials Guidance. URL: www.hra.nhs.uk/documents/2014/04/
nres-guidance_informed-consent-ctimps_v3-1_2014-04-14.pdf (accessed 15 July 2014).
60. Reed J, Cook G, Cook M. Research governance issues in the care home sector. J Res Nurs
2004;9:430–9. http://dx.doi.org/10.1177/136140960400900604
61. Lingler JH, Jablonski RA, Bourbonniere M, Kolanowski A. Informed consent to research in
long-term care settings. Res Gerontol Nurs 2009;2:153–61. http://dx.doi.org/10.3928/
19404921-20090428-03
62. Kaasalainen S, Williams J, Hadjistavropoulos T, Thorpe L, Whiting S, Neville S, et al. Creating
bridges between researchers and long-term care homes to promote quality of life for residents.
Qual Health Res 2010;20:1689–704. http://dx.doi.org/10.1177/1049732310377456
63. Washington AE, Lipstein SH. The patient centred outcomes research institute – promoting better
information, outcomes and health. N Engl J Med 2011;365:e31. http://dx.doi.org/
10.1056/NEJMp1109407
64. Oliver S, Clarke-Jones L, Rees R, Milne R, Buchanan P, Gabbay J, et al. Involving consumers in
research and development agenda setting for the NHS: developing an evidence-based approach.
Health Technol Assess 2004;8(15).
65. National Institute for Health Research. Patient and Public Involvement – Information for
Researchers. URL: www.nets.nihr.ac.uk/data/assets/pdf_file/0015/70026/ppi-researchers.pdf
(accessed 17 July 2014).
66. National Institute for Health Research. Enabling Research in Care Homes (ENRICH). NIHR.
URL: www.enrich.dendron.nihr.ac.uk (accessed 17 July 2014).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
67. British Geriatrics Society Joint Working Party. Quest for Quality: An Inquiry into the Quality of
Healthcare Support for Older People in Care Homes: A Call for Leadership, Partnership and
Improvement. London: British Geriatrics Society; 2011. URL: www.bgs.org.uk/campaigns/
carehomes/quest_quality_care_homes.pdf (accessed 22 July 2014).
68. Harris R, Dyson E. Recruitment of frail older people to research: lessons learnt through experience.
J Adv Nurs 2001;35:643–51.
69. Crome P, Lally F, Cherubini A, Oristrell J, Beswick AD, Clarfield AM, et al. Exclusion of older people
from clinical trials. Drugs Aging 2011;28:667–77. http://dx.doi.org/10.2165/11591990-
000000000-00000
70. Cherubini A. Increasing the Participation of the Elderly in Clincal Trials (PREDICT). Sheffield: Medical
Economics and Research Centre; 2010. URL: www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2012/04/WC500125146.pdf (accessed 17 July 2014).
71. Luff R, Ferreira Z, Meyer J. Methods Review No. 8 Care Homes. National Institute for Health
Research School for Social Care Research, 2011. URL: http://sscr.nihr.ac.uk/PDF/MR/MR8.pdf
(accessed 17 July 2014).
72. National Institute for Health Research. UK Clinical Research Network Patient and Public Involvement
Strategy [11/11/2013]. URL: www.crn.nihr.ac.uk/can-help/healthcare-professionals/involving-
patients-in-research/ (accessed 17 July 2014).
73. National Institute for Health Research. INVOLVE: National Institute for Health Research.
URL: www.invo.org.uk (accessed 11 November 2013).
74. Viergever RF, Olifson S, Ghaffar A, Terry RF. A checklist for health research priority setting:
nine common themes of good practice. Health Res Policy 2010;8:36.
75. Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research
tool for general practice? Fam Pract 1993;10:76–81. http://dx.doi.org/10.1093/fampra/10.1.76
76. Hall S, Longhurst S, Higginson IJ. Challenges to conducting research with older people living in
nursing homes. BMC Geriatr 2009;9:38. http://dx.doi.org/10.1186/1471-2318-9-38
77. Zermansky AG. Including care home residents in clinical research is fraught. BMJ
2005;331:1271–2. http://dx.doi.org/10.1136/bmj.331.7527.1271-c
78. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester:
Wiley-Blackwell; 2008. http://dx.doi.org/10.1002/9780470712184
79. Lievesley N, Crosby G, Bowman C. The Changing Role of Care Homes. London: Centre for Policy
on Ageing; 2011.
80. Goodman C, Baron NL, Machen I, Stevenson E, Evans C, Davies SL, et al. Culture, consent, costs
and care homes: enabling older people with dementia to participate in research. Aging Ment
Health 2011;15:475–81. http://dx.doi.org/10.1080/13607863.2010.543659
81. Russell CA, Elia M. Nutrition Screening Survey in the UK and Republic of Ireland in 2010. A Report
by the British Association for Parenteral and Enteral Nutrition (BAPEN). Redditch: BAPEN; 2011.
82. Roberts C, Roberts J, Roberts RJ. Survey of healthcare-associated infection rates in a nursing home
resident population. J Infect Prev 2010;11:82–6.
83. Eklund Å, Hartvig P, Tverin I, Palm M, Sylvan S. Prevalence and management of infections in
nursing homes in Uppsala County, Sweden. Open Longev Sci 2008;2:96–9. http://dx.doi.org/
10.2174/1876326X00802010096
DOI: 10.3310/hta18630 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 63
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Hood et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
73
84. Lonnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of Lactobacillus
plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin
Gastroenterol 2010;44:106–12. http://dx.doi.org/10.1097/MCG.0b013e3181b2683f
85. Song HJ, Kim JY, Jung SA, Kim SE, Park HS, Jeong Y, et al. Effect of probiotic Lactobacillus
(Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized,
double-blind, multicenter study. J Korean Med Sci 2010;25:1784–91. http://dx.doi.org/10.3346/
jkms.2010.25.12.1784
86. Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of
extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an
Israeli long-term care facility. Eur J Clin Microbiol Infect Dis 2005;24:17–22. http://dx.doi.org/
10.1007/s10096-004-1264-8
87. Dixon-Woods M, Ashcroft RE, Jackson CJ, Tobin MD, Kivits J, Burton PR, et al. Beyond
“misunderstanding”: written information and decisions about taking part in a genetic
epidemiology study. Soc Sci Med 2007;65:2212–22. http://dx.doi.org/10.1016/j.socscimed.
2007.08.010
88. Jefford M, Moore R. Improvement of informed consent and the quality of the consent document.
Lancet Oncol 2008;9:485–93. http://dx.doi.org/10.1016/S1470-2045(08)70128-1
89. Bayer A, Fish M. The doctor’s duty to the elderly patient in clinical trials. Drugs Ageing
2003;20:1087–97. http://dx.doi.org/10.2165/00002512-200320150-00002
90. Young J, Inouye SK. Delirium in older people. BMJ 2007;334:842. http://dx.doi.org/10.1136/
bmj.39169.706574.AD
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
Appendix 1 Participant flow diagram
Care home and local GP recruited.
Residents/relatives/nurses/GPs informed about the trial
All/as many as possible residents consent/assent to join the trial
Participant prescribed a course of systemic antibiotic therapy by GP
Participant rechecked against eligibility criteria
Baseline assessment (day 1) on eligible participant (history, nutritional risk, QoL, etc.)
Participant is allocated next sequential study
medication pack which contains either
Two doses of probiotic per day for
21 days
Two doses of placebo per day for
21 days
8-week follow-up (from start of study medication)
Stool sample is
taken and sent off
for C. difficile analysis
at local laboratory
8-week follow-up involves:
(1)
(2)
(3)
participant completes daily diary (data on study,
non-study medication use, side effects, health
resource utilisation and nutritional risk)
simple daily stool chart
QoL questionnaire (EQ-5D) and health economics
data – weekly
Diarrhoea
within 8 weeks
No diarrhoea
within 8 weeks
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Appendix 2 Study schema
Ethics approval for multicentre trial
Recruit participating care homes
(n = 24)
Approach residents
(n = 1214)
Recruit and consent residents
(n = 607)
Residents prescribed antibiotics and reassessed for eligibility
Randomisation
(n = 400)
Prescribed for 21 days
8-week follow-up
Daily diary
Weekly EQ-5D
Control (placebo)
(n = 200)
8-week follow-up
Daily diary
Weekly EQ-5D
Health-care
resource use
Health-care
resource use
Stool sample sent to laboratory
Episode of diarrhoea
Within
72 hours
Study medication (probiotic)
(n = 200)
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Appendix 3 Research priority topics
P lease score the six topics you feel is the most important from 1 to 6 (1 is least important, 6 is the mostimportant of your chosen six topics).
Topic Number
1. How can care home staff best be kept up to date with staff development/evidence updates for nurses in
care homes?
e.g. 3
2. How can hospital care for older people from care homes be improved? (Service configurations and
interactions between care homes and hospital)
3. What are the best methods of diagnosing UTIs in elderly women and what methods can be used for
collecting reliable urine samples?
4. Are there ways UTIs can be prevented and how can UTIs be predicted?
5. How can access to speech and language therapy be improved? (Is there potential to increase skill in care
home staff to assess speech and language problems and support speech and language needs)
6. How can access to physiotherapy services be improved?
7. How can the current multiple and complex care referral pathways be improved so as to reduce the long
waits and wasted resources? (Care appears to be organised around professional services rather than the
patient, are there ways to make the process person centred)
8. Does participation in activities reduce levels of anxiety and depression levels in residents?
9. How can communication between staff and hospitals be improved when residents move into and out of
hospitals? Can the prescribing and dispensing of medication process be improved to reduce wasted time
and resources?
10. What is the evidence for the use of bedrails to reduce the risk of entrapment? (Particularly with the use of
airflow mattresses)
11. What are safe procedures for the use of airflow mattresses for people weighing less than 50 kg? (Currently
not suitable for those below 50 kg, but no currently recommended alternative available)
12. Do different models of interaction with GPs (how often doctors visit and whether it is the same doctor)
impact on residents’ urgent care requirements or hospital admissions?
13. Is there evidence of an impact of changing nutritional patterns on moving in to a care home, compared
with prior to moving in, on nutritional status?
14. How can the Butterfly scheme/This Is Me books improve transfers between care home and hospital?
15. Does the use of Bristol Stool Chart benefit care home residents, or result in best practice/
improving standards?
16. What is the impact of use of ‘food first programme’, instead of prescribable dietary supplements, on
residents’ nutrition?
17. Can we improve hydration by improving use of prethickened fluids instead of care home staff preparing
drinks using thickening agents?
18. What are the benefits of participating in tai chi in wellbeing of care home residents?
19. Can the administration of i.v. fluids and antibiotics in care homes improve the health of residents and
prevent hospital admissions?
20. What improvements can be made in access to dental care for residents? And how effective are techniques
to improve oral hygiene, such as use of suction/rinse toothbrushes?
21. What are the benefits of different types of activity provision for care home residents, such as peer
led groups?
22. What are the benefits of the use of sensory techniques in provision of activities for care home residents?
23. What are the safe minimum staffing levels and how do these relate to dependency scoring? How many
staff do you actually need in care homes?
i.v., intravenous.
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Appendix 4 Research priority rank ordering
Priorities for research in care homes
Topic
Priority
ranking
from
workshop
Score
from
workshop
Priority
ranking
from
postal
survey
Score
from
postal
survey
Total
score
Rated as important,
but not individually
scored (information
only)
1. How can care home staff best
be kept up to date with staff
development/evidence updates
for nurses in care homes?
2, 4 8 2 5 13
2. How can hospital care for
older people from care
homes be improved? (Service
configurations and interactions
between care homes and
hospital)
Joint 1 6 3 4 10 Marked as
important twice
3. What are the best methods of
diagnosing UTIs in elderly
women and what methods can
be used for collecting reliable
urine samples?
1 6 Joint 1 6 12 Marked as
important three times
4. Are there ways UTIs can be
prevented and how can UTIs
be predicted?
Joint 1,
6, 4
10 10 Marked as
important twice
5. How can access to speech and
language therapy be improved?
(Is there potential to increase
skill in care home staff to assess
speech and language problems
and support speech and
language needs?)
6. How can access to
physiotherapy services
be improved?
7. How can the current multiple
and complex care referral
pathways be improved so as to
reduce the long waits and
wasted resources? (Care
appears to be organised around
professional services rather than
the patient, are there ways to
make the process person
centred)
4, 1, 5 11 11 Marked as
important once
8. Does participation in activities
reduce levels of anxiety and
depression levels in residents?
Marked as
important once
9. How can communication
between staff and hospitals be
improved when residents move
into and out of hospitals? Can
the prescribing and dispensing
of medication process be
improved to reduce wasted time
and resources?
Joint 1, 3 10 3, 2 9 19 Marked as
important twice
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Topic
Priority
ranking
from
workshop
Score
from
workshop
Priority
ranking
from
postal
survey
Score
from
postal
survey
Total
score
Rated as important,
but not individually
scored (information
only)
10. What is the evidence for the
use of bedrails to reduce the
risk of entrapment?
(Particularly with the use of
airflow mattresses)
Joint 5 2 Joint 5 2 4 Marked as
important once
11. What are safe procedures for
the use of airflow mattresses
for people weighing less than
50 kg? (Currently not suitable
for those below 50 kg, but no
currently recommended
alternative available)
Joint 5 2 Joint 5 2 4
12. Do different models of
interaction with GPs (how
often doctors visit and
whether it is the same doctor)
impact on residents urgent
care requirements or hospital
admissions?
6, 5 3
13. Is there evidence of an impact
of changing nutritional
patterns on moving in to a
care home, compared with
prior to moving in, on
nutritional status?
14. How can the Butterfly scheme/
This Is Me books improve
transfers between care home
and hospital?
Marked as
important once
15. Does the use of Bristol Stool
Chart benefit care home
residents, or result in best
practice/improving standards?
Marked as
important once
16. What is the impact of using
the ‘food first programme’,
instead of prescribable dietary
supplements, on residents’
nutrition?
17. Can we improve hydration by
improving the use of
prethickened fluids instead of
care home staff preparing
drinks using thickening
agents?
18. What are the benefits of
participating in tai chi on the
wellbeing of care home
residents?
6 1 1
19. Can the administration of i.v.
fluids and antibiotics in care
homes improve the health of
residents and prevent
hospital admissions?
Joint 6 1 1 Marked as
important once
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Topic
Priority
ranking
from
workshop
Score
from
workshop
Priority
ranking
from
postal
survey
Score
from
postal
survey
Total
score
Rated as important,
but not individually
scored (information
only)
20. What improvements can be
made in access to dental care
for residents? And how
effective are techniques to
improve oral hygiene, such
as use of suction/rinse
toothbrushes?
5 2 4, 1 9 11
21. What are the benefits of
different types of activity
provision for care home
residents, such as peer
led groups?
22. What are the benefits of the
use of sensory techniques in
provision of activities for care
home residents?
Marked as
important once
23. What are the safe minimum
staffing levels and how do these
relate to dependency scoring?
How many staff do you actually
need in care homes?
4, 6 4 3, 2 6 10 Marked as
important once
i.v., intravenous.
Priorities for research in care homes: rank ordering
1 How can communication between staff and hospitals be improved when residents move into and out of hospitals?
Can the prescribing and dispensing of medication process be improved to reduce wasted time and resources?
2 How can care home staff best be kept up to date with staff development/evidence updates for nurses in
care homes?
3 What are the best methods of diagnosing UTIs in elderly women and what methods can be used for collecting
reliable urine samples?
= 4 How can the current multiple and complex care referral pathways be improved so as to reduce the long waits and
wasted resources? (Care appears to be organised around professional services rather than the patient, are there
ways to make the process person-centred)
= 4 What improvements can be made in access to dental care for residents? And how effective are techniques to
improve oral hygiene, such as use of suction/rinse toothbrushes?
= 6 Are there ways UTIs can be prevented and how can UTIs be predicted?
= 6 What are the safe minimum staffing levels and how do these relate to dependency scoring? How many staff do
you actually need in care homes?
= 6 How can hospital care for older people from care homes be improved? (Service configurations and interactions
between care homes and hospital)
= 9 What is the evidence for the use of bedrails to reduce the risk of entrapment? (Particularly with the use of
airflow mattresses)
= 9 What are safe procedures for the use of airflow mattresses for people weighing less than 50 kg? (Currently not
suitable for those below 50 kg, but no currently recommended alternative available)
= 11 What are the benefits of participating in tai chi on the wellbeing of care home residents?
= 11 Can the administration of i.v. fluids and antibiotics in care homes improve the health of residents and prevent
hospital admissions?
i.v., intravenous.
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